

**An-Najah National University**

**Faculty of Graduate Studies**

**Relationship of Omega-3 Status with Diabetes Mellitus**

**Type 2 Control Measurements in Nablus City**

**By**

**Fatma Hisham Bakri**

**Supervisors**

**Dr. Mariam Amer Al-Tal**

**Dr. Nihal Natour**

**This Thesis is Submitted in Partial Fulfillment of the Requirements for  
The Degree of Master in Public Health, Faculty of Graduate Studies,  
An-Najah National University, Nablus-Palestine.**

**2020**

**Relationship of Omega-3 Status with Diabetes Mellitus  
Type 2 Control Measurements in Nablus City**

**By**

**Fatma Hisham Bakri**

This Thesis was Defended Successfully on 17/09/2020 and approved by:

**Defense Committee Members**

**Signatures**

1. Dr. Mariam Amer Al-Tal/ Supervisor

.....

2. Dr. Nihal Natour/ Supervisor

.....

3. Dr. Manal Badrasawi/Internal Examiner

.....

4. Dr. Sana' AL-Aqqad/ External Examiner

.....

### III

## Dedication

I would like to offer gratitude and appreciation to my special supervisors, Dr. Mariam Al-Tal and Dr. Nihal Natour, for providing their support and guidance along the way. I am also grateful to my parents, my husband, and my friends, who helped me to go through really hard times. I would like to show them my gratitude because they were so patient and understanding and their encouragement made it possible to achieve my goal.

## **Acknowledgement**

The study was conducted by Fatma Hisham Bakri, an MPH graduate at An-Najah National University-Nablus. It is supervised by Dr. Mariam Amer Al-Tal and Dr. Nihal Natour of the Faculty of Medicine and Health Sciences at An-Najah National University-Nablus.

The preparation of this study would not have been possible without the collaboration of the Palestinian Ministry of Health (Nablus, Ramallah and Balata), the Faculty of Graduate Studies at An-Najah National University-Nablus, and all of the participants at the Almahfeye Clinic in Nablus City. I would like to thank everyone who works there and helped me to complete my study.

I am especially thankful to Dr. Mariam Al-Tal and Dr. Nihal Natour for their constant guidance, assistance, and wisdom as well as the laboratory staff, Mr. Rami Basalat and Ms. Lubna, for the instructions and directions during the laboratory work hours.

Of course, I am grateful to my parents, Hisham and Maha, my husband Kefah, my family and friends, whose support was the main reason of this success and because they always encourage me to do my best.

Special thanks to the Galilee Society led by Dr. Sobhe Bsher for giving me the opportunity to use the GC system.

## الإقرار

أنا الموقع أدناه مقدم الرسالة التي تحمل العنوان:

**The Relationship of Omega-3 Status with Diabetes Mellitus Type 2****Control Measurements in Nablus City**

العلاقة بين حالة أوميغا 3 وقياسات التحكم لمريض السكري النوع الثاني في مدينة نابلس

أقر بأن ما اشتملت عليه هذه الرسالة إنما هي نتاج جهدي الخاص، باستثناء ما تمت الإشارة إليه  
حيثما ورد، وأن هذه الرسالة ككل، أو أي جزء منها لم يقدم لنيل أية درجة أو لقب علمي أو بحثي  
لدى أية مؤسسة تعليمية أو بحثية أخرى.

**Declaration**

The work provided in this thesis, unless otherwise referenced, is the  
researcher's own work and has not been submitted elsewhere for any other  
degree or qualification.

**Student's name: Fatma Hisham Bakri**

اسم الطالب: فاطمة هشام بكري

**Signature:.....**

التوقيع:.....

**Date: 17/9/2020**

التاريخ: 2020/9/17

VI  
**List of Contents**

<b>Number</b>	<b>Content</b>	<b>Pages</b>
	Discussion paper	II
	Dedication	III
	Acknowledgement	IV
	Declaration	V
	List of Contents	VI
	List of Tables	IX
	List of Figures	X
	List of Appendices	X
	List of Abbreviations	XI
	Study Terms	XIII
	Abstract	XIII
	<b>Chapter 1</b>	1
1.1	Background	1
1.2	Metabolism of Omega-3 PUFAs	3
1.3	Dietary Sources of Omega-3 FAs and their Recommended Intake	4
1.4	Analysis of Omega-3 FAs	6
1.5	Insulin Resistance and Omega-3 FAs	6
1.6	Study Justification and Problem Statement	7
1.7	Objectives of the Study	8
1.8	Research Questions	8
	<b>Chapter 2: Literature Review</b>	10
2.1	Relationship between Omega-3 FAs and DMT2	10
2.2	Relationship between Omega-3 Index and DMT2	15
	<b>Chapter 3: Methodology</b>	19
3.1	Introduction	19
3.2	Study Design	19
3.3	Study Site and Setting	19
3.4	Population and Sample Size	19
3.4.1	Population	19
3.4.2	Sample Size and sampling method	20

3.4.3	Inclusion Criteria	20
3.4.4	Exclusion Criteria for Study Group	20
3.5	Data Collection Tool	20
3.5.1	Study Questionnaire	20
3.5.1.1	Part One	21
3.5.1.1.1	Socio-Demographic Data	21
3.5.1.1.2	Information Regarding Medical History	21
3.5.1.1.3	Anthropometric Measurements	21
3.5.1.1.4	Dietary Assessment	22
3.5.1.2	Part Two	22
3.5.1.2.1	Biochemical Tests	22
3.5.2	Validity and Reliability	23
3.5.3	Pilot Study	23
3.6	Field Work and Procedure	23
3.6.1	Determination of Omega-3 Index	24
3.6.1.1	Analysis of Omega-3 FAs	24
3.6.1.2	Determination of Omega-3 Index	25
3.6.1.3	Chemicals and Biochemical Reagents	25
3.6.1.4	Equipment	25
3.7	Statistical Methods and Data Analysis	26
3.8	Ethical Consideration and Accessibility	27
	<b>Chapter 4: Results</b>	28
4.1	Socio-demographic Data	28
4.2	Anthropometric Measurements	29
4.3	Evaluation of Omega-3 FAs Intake	30
4.4	Biochemical Tests	31
4.5	Evaluation of FAs and Omega-3 Index	32
4.6	Association between Omega-3 Index and Omega-3 FAs Intake	33
4.7	Association between Omega-3 Index and Controlling Measurements	33
4.8	Association between Omega-3 FAs Intake and Controlling Measurements	34
	<b>Chapter 5: Discussion</b>	35

## VIII

5.1	Description of the Study	35
5.2	Evaluation of Anthropometric Measurements	35
5.3	Evaluation of Omega-3 FAs Intake	37
5.4	Evaluation of Omega-3 Index	38
5.5	Relationship between Omega-3 FAs Intake and Index	38
5.6	Relationship between the Omega-3 Index and Controlling Measurements	39
5.6.1	Relationship between Omega-3 Index and Blood Glucose and HbA1c Levels	39
5.6.2	Relationship between the Omega-3 Index and Blood Triglycerides Level	40
5.7	Relationship between Omega-3 FAs Intake and Controlling Measurements	42
5.7.1	Relationship between Omega-3 FAs Intake and Blood Glucose and HbA1c Levels	42
5.7.2	Relationship between the Omega-3 FAs Intake and Blood Triglycerides Level	43
5.8	Strengths of the Study	44
5.9	Difficulties of the Study	44
5.10	Conclusion	45
5.11	Recommendations	45
5.12	Implications of the Study	45
5.13	Limitations of the Study	46
	References	47
	Appendices	58
	الملخص بالعربي	ب

## List of Tables

<b>Number</b>	<b>Table Caption</b>	<b>Page</b>
Table 1.1	Dietary sources of ALA and the required amount to meet adequate intakes	5
Table 1.2	EPA and DHA content in some types of fish	5
Table 3.1	Conceptual and operational definitions of HbA1c, glucose and triglycerides blood glucose levels, omega-3 index and omega-3 FAs intake	26
Table 4.1	Distribution of participants according to their demographic characteristics	28
Table 4.2	Distribution of participants regarding their anthropometric measurements	2
Table 4.3	Distribution of participants regarding their omega-3 FAs intake from fish sources	30
Table 4.4	Distribution of participants regarding their average omega-3 FAs intake over the last 3 months	30
Table 4.5	Distribution of participants according to their controlling measurements	31
Table 4.6	Mean and SD values of FAs in plasma and omega-3 index of participants	32
Table 4.7	Association between omega-3 index and omega-3 FAs intake using Pearson correlation coefficient	33
Table 4.8	Association between omega-3 index and controlling measurements using Pearson correlation coefficient	33
Table 4.9	Association between omega-3 FAs intake and controlling measurements using Pearson correlation coefficient	34

## List of Figures

Number	Figure Caption	Page
1	Cut-off points for omega-3 index	3

## List of Appendices

Number	Appendix Caption	Page
1	English Questionnaire	58
2	Arabic Questionnaire	64
3	An-Najah National University - Institutional Review Board (IRB) Ethical Approval	68
4	An-Najah National University – Graduate Studies Approval	69
5	Palestinian Ministry of Health’s Letter of Approval	70
6	The Distribution of Omega-3 intake Regarding the Food Type Participants Ate Regularly over the Last Three (3) Months	71
7	قائمة المتناول من الطعام	74

**List of Abbreviations**

<b>AA</b>	Arachidonic Acid
<b>ALA</b>	Alpha-Linolenic Acid
<b>BMI</b>	Body Mass Index
<b>CAFÉ</b>	Compositional Analyses from Frequency Estimates program
<b>CHD</b>	Coronary Heart Disease
<b>CVD</b>	Cardiovascular Disease
<b>DHA</b>	Docosahexaenoic Acid
<b>DMT2</b>	Diabetic Mellitus Type Two
<b>EFSA</b>	European Food Safety Authority
<b>EPA</b>	Eicosapentaenoic Acid
<b>FAO</b>	Food and Agriculture Organization
<b>FAs</b>	Fatty Acids
<b>FFQ</b>	Food Frequency Questionnaire
<b>GBD</b>	Global Burden of Disease
<b>GC</b>	Gas Chromatography
<b>HbA1c</b>	Glycated Hemoglobin
<b>IDF</b>	International Diabetes Federation
<b>IRB</b>	Institutional Review Board
<b>LA</b>	Linoleic Acid
<b>MENA</b>	Middle East and North Africa
<b>PMoH</b>	Palestinian Ministry of Health
<b>PUFAs</b>	PolyUnsaturated Fatty Acids
<b>RBCs</b>	Red Blood Cells
<b>SD</b>	Standard Deviation
<b>USDA</b>	United States Department of Agriculture
<b>WHO</b>	World Health Organization

## **Study Terms**

### **DMT2**

Diabetes Mellitus Type 2 (adult-onset diabetes) is a form of diabetes that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, and unexplained weight loss.

### **Omega 3 Index**

Omega-3 index is the sum of EPA and DHA in the blood (plasma or RBC). It is expressed as the percentage of the total FAs present the blood.

### **Omega 3**

Omega-3 fatty acids (FAs) belong to the group of polyunsaturated fatty acids (PUFAs).

### **Gas Chromatography**

Gas chromatography (GC) is used nowadays to analyze different types of FAs.

**Relationship of Omega-3 Status with Diabetes Mellitus Type 2 Control Measurements in Nablus City**

By

**Fatma Hisham Bakri**

Supervisor

**Dr. Mariam Amer Al-Tal****Dr. Nihal Natour****Abstract**

Various studies suggest that the dietary intake of omega-3 fatty acids (FAs) has the potential to prevent serious medical conditions, including diabetes mellitus type 2 (DMT2). Even though DMT2 is one of the major chronic diseases in Palestine, omega-3 index has not been evaluated among healthy or Palestinian adults diagnosed with DMT2 on a population level.

**Aim of the Study:** The study aimed at evaluating the omega-3 status in the selected group of Palestinian adults diagnosed with DMT2.

**Methodology:** A quantitative cross-sectional study was conducted on 105 DMT2 Palestinian patients in Nablus City. Total consumption of dietary omega-3 FAs over the last three months was assessed using a Food Frequency Questionnaire (FFQ). Controlling measurements including glycated hemoglobin (HbA1c), blood glucose level and blood triglycerides level were analyzed after obtaining blood samples from each patient and omega-3 FAs were analyzed using gas chromatography (GC).

**Results:** The study revealed that omega-3 index was extremely low with a mean of  $0.26 \pm 2.15$ , while omega-3 FAs mean intake was  $1.04 \pm 0.90$  g/day which was within the “Acceptable Macronutrient Distribution Range” (AMDR) values. In addition, there was a positive but not significant ( $P \geq$

0.05) relationship ( $r= 0.047$ ) between omega-3 FAs intake and omega-3 index. On the other hand, there were negative but not significant ( $P \geq 0.05$ ) relationships between omega-3 index and HbA1c ( $r= -0.021$ ), omega-3 index and blood glucose level ( $r= -0.14$ ) and between omega-3 index and blood triglycerides level ( $r= -0.11$ ).

**Conclusion:** The study concluded that a linear relationship existed between omega-3 index and omega-3 FAs intake. That is, the higher the intake, the higher is omega-3 index. It also concluded that the sufficient intake of omega-3 FAs had a lowering effect on blood glucose level, HbA1c and blood triglyceride level.

**Recommendations:** It is recommended for stakeholders to assess omega-3 index among DMT2 patients in the RBC rather than plasma, and to apply the study including patients with DMT2 from all cities of Palestine.

**Keywords**

Omega-3 Intake, Omega-3 Index, DMT2, Gas Chromatography, Controlling Measurements.

# Chapter 1

## 1.1 Background

Worldwide, DMT2 is an epidemic as the number of patients is growing and expected to increase greatly in the following years (**Shaw *et al.*, 2010**). Several long-term vascular complications may be caused by this condition such as chronic kidney disease, stroke, peripheral vascular disease, heart disease and death. In addition, extra weight and obesity are likely to appear as a result of these complications (**Colosia *et al.*, 2013**).

The worldwide existing prevalence of DMT2 is about 425 million people (International Diabetic Federation Diabetes, 2018). In 2019, the new reported DMT2 cases in PMoH Primary Health Care diabetic clinics in the West Bank were 5,671 cases (573 in Nablus alone) with an incidence rate of 210.4 per 100,000 populations, distributed to 2,505 cases among males with an incidence rate of 182.7 per 100,000 populations and 3,166 among females with an incidence rate of 239.1 per 100,000 populations (**Palestinian Ministry of Health, 2019**).

Omega-3 FAs belong to the poly-unsaturated fatty acids (PUFAs) group and possess several health benefits. For instance, they play a major role in preventing coronary heart disease (CHD), Crohn disease, prostate and colon cancer, autoimmune diseases such as nephropathy and lupus, rheumatoid arthritis and mild hypertension (Connor, 2000).

The most important omega-3 FAs are EPA, DHA, and Alpha-Linolenic Acid (ALA). Fish is the richest source of EPA and DHA, whereas some plant-derived foods such as flaxseeds, walnuts, canola and their oils

are the richest sources of ALA (**Bradberry and Hilleman, 2013**). However, due to the inefficient conversion of ALA to EPA and DHA, its extremely important to supply the human body with these two essential FAs from external sources (dietary intake of certain foods). Fatty fish such as salmon, albacore tuna, sardines, herring and mackerel are the richest sources of EPA and DHA. Other foods include eggs and meat (**Weylandt *et al.*, 2015**).

Omega-3 index is the sum of EPA and DHA in RBCs membrane and is expressed as a percentage of the total FAs present in RBCs (Harris, 2007). It is usually used in nutritional studies to indicate the medium and long-term intake of Omega-3 FAs (**Abu and Oluwatowoju, 2009**). This index is considered a risk factor of death from CHD (**Harris, 2007**). Harris (2007) proposed the cut-off points of omega-3 index (figure 1), and defined low, intermediate and high risk levels of omega-3 index ( $> 8\%$ ,  $4\%–8\%$  and  $< 4\%$  respectively).


Importantly, in regions where omega-3 FAs are frequently consumed, omega-3 index is high. It is estimated that the average omega-3 index is 4-5% in USA, whereas in Japan, it is much higher (9-10%). As a result, cardiovascular diseases (CVD) are less common, which leads to a longer lifespan. Whereas, very low levels of omega-3 index ( $\leq 4\%$ ) was reported in the Middle East, Central and South America, Africa and Southeast Asia (**Stark *et al.*, 2016**).

Omega-3 index is influenced by several factors such as gender, physical activity, age, Body Mass Index (BMI), diabetes and drinking alcohol (Von Schacky, 2010). The EPA and DHA intake significantly

affects omega-3 index, where each 4g of the ingested EPA and DHA per month cause an increase of 0.24% in omega-3 index value (Von Schacky, 2010).

## 1.2 Metabolism of Omega-3 PUFAs.

Omega-3 and omega-6 PUFAs are essential to the human body, and undergo several metabolic pathways through which are converted into longer chain FAs by the elongation of the hydrocarbon chains (up to 20-22 carbon atoms) and by the desaturation (addition of extra double bonds) (Simopoulos, 1991).



**Figure 1: Cut-off points for omega-3 index.**  
Source: Harris and Von Schacky (2004).

ALA and linoleic acid (LA) are the parents of omega-3 and omega-6 FAs families, respectively. ALA is elongated into EPA and DHA whereas LA is converted into arachidonic acid (AA). Both families compete for the same enzyme that is responsible for their desaturation and chain elongation (Nabavi *et al.*, 2015).

For example,  $\Delta$ -6-desaturase enzyme, which converts ALA to EPA and DHA, prefers ALA over LA. However, the conversion of ALA has two limitations. The increased intake of omega-6 PUFAs increases the level of metabolism of LA, and consequently, the enzymatic action is shifted toward the metabolism of omega-6 PUFAs pathway (**Budowski, 1988**). The shift will inhibit the conversion of ALA to EPA and DHA, which represents the first limitation. The other limitation is that the conversion of ALA to EPA and DHA is inefficient (**Gerster, 1998**). In addition, elongation and desaturation of ALA and LA are disturbed with the intake of Trans FAs (**Hague and Christoffersen, 1984; Hagve and Christoffersen, 1986**).

### **1.3 Dietary Sources of Omega-3 FAs and their Recommended Intake**

The most common dietary sources of ALA and the required amount to meet adequate intakes are demonstrated in Table 1.1 (**Gebauer *et al.*, 2006**). Whereas, Table 1.2 summarizes EPA and DHA content in some types of fish (**Buzby and Hyman, 2012**). On the other hand, AA is found in dairy, eggs and in the phospholipids of grain-fed animals (**Nabavi *et al.*, 2015**).

**Table 1.1: Dietary sources of ALA and the required Amount to meet adequate intakes.**

Source of ALA	ALA	Amount needed by women to meet recommendation (1.1 g ALA/day)	Amount needed by men to meet recommendation (1.6 g ALA/day)
	g/tbsp.	tbsp.	tbsp.
Pumpkin seeds	0.051	21.6	31.4
Walnuts, black	0.156	7.05	10.3
Soybean oil	1.231	0.89	1.3
Rapeseed oil	1.302	0.84	1.2
Walnut oil	1.414	0.78	1.1
Flaxseeds	2.350	0.47	0.68
Walnuts,	2.574	0.43	0.62
Flaxseed oil	7.249	0.15	0.22

Source: Gebauer *et al.* (2006).

Note: Tbsp: table spoon.

**Table 1.2: EPA and DHA content in some types of fish.**

Fish	EPA + DHA	Amount needed to get 500 mg EPA + DHA/day	Amount needed to get 500 mg EPA + DHA/day
	Mg/Serving	Serving	Servings/Week
Shrimp	267	1.9	13.3
Tuna, canned	733	0.68	4.8
Salmon	1825	0.27	1.9

Source: Buzby and Hyman (2012).

Note: 1 serving = 85 g (3 oz.) cooked portions.

According to Food and Agriculture Organization (FAO) and World Health Organization (WHO), the AMDR value of omega-3 PUFAs (including ALA and long-chain omega-3 FAs) is estimated as 0.5-2% from total energy intake. In addition, the AMDR of EPA+ DHA is estimated as 0.25-2 g/day (Joint FAO/WHO, 2008).

European Food Safety Authority (EFSA) has reported that the excess intake of omega-3 FAs leads to abnormal bleeding, increased lipid peroxidation, impaired immune functions and impaired glucose and lipid metabolism (EFSA, 2012).

#### **1.4 Analysis of Omega-3 FAs**

GC is frequently used to analyze different types of FAs. This technique is sensitive, robust and accurate (Abu and Oluwatowoju, 2009). Samples of FAs should undergo derivatization in order to become more volatile and, therefore, eluted at specific temperatures. The derivatization insures that FAs will not be decomposed at higher temperatures. One of the most common derivatization methods is methylation, by which free FAs are released from lipids through the hydrolysis of ester bonds. In this case, free FAs are converted to FA methyl esters (FAMES) by the trans-methylation method. FAMES are used to refer to the FAs composition. Therefore, GC is used to determine the concentration of free FAs in the sample (Burdge *et al.*, 2000). Analysis of FAs requires three major steps: 1) extracting the lipid phase from tissues or cells, 2) the methylation step and 3) injecting the sample in question into the injection port of the GC (Mesood *et al.*, 2005; Kuriki *et al.*, 2006; Ratnayake and Galli, 2009).

#### **1.5 Insulin Resistance and Omega-3 FAs.**

Insulin sensitivity is influenced by many factors such as adiposity, age, genotype and perinatal factors. In addition, physical activity and diet,

which are considered modifiable lifestyle factors, affect insulin activity (Kim *et al.*, 2007). Although increasing the physical activity and weight loss may improve insulin sensitivity, this goal is difficult to achieve for a large population. It was found that small dietary modifications such as increased intake of fish or the dietary supplementation may enhance insulin sensitivity, thus reducing the risk of DMT2, the metabolic syndrome and CVD (Albert *et al.*, 2014). It was reported that insulin resistance is inversely associated with omega-3 index due to its anti-inflammatory effect. In addition, it could be used as a reflective biomarker for pro-inflammatory diseases (Thomas and Garg, 2016).

## **1.6 Study Justification and Problem Statement**

DMT2 is one of the major chronic diseases in the West Bank (Mosleh *et al.*, 2016). The benefits of omega-3 FAs and their positive effects on inflammation, which is strongly linked to DMT2, are obvious (Ellulu *et al.*, 2016). Therefore, it is important to raise the awareness about omega-3 FAs at a population level. Unfortunately, the measurement of omega-3 index is unavailable in the West Bank (including Nablus) due to the high cost of operation. Therefore, it is important to determine the relationship between omega-3 index, omega-3 FAs intake and DMT2.

Therefore, this study and its results focus on the importance of omega-3 index and omega-3 FAs intake among Palestine adults diagnosed with DMT2. The results of the current study will draw more attention to the importance of omega-3 FAs to health, the risks associated with low omega-

3 levels and its consequences. The study will also help diabetics and physicians to identify and maintain correct omega-3 levels.

Furthermore, this study will provide some strategies to bring awareness and instruct the majority of people living in Palestine about the benefits of omega-3 index and intake from dietary sources or as supplements. Due to the related prevalence of DM in Palestine, we concluded that it is important to study the impact of omega-3 on diabetics and their health.

### **1.7 Objectives of the Study**

1. To evaluate omega-3 index in selected groups of Palestinian adults diagnosed with DMT2.
2. To evaluate the dietary intake of omega-3 FAs in selected groups of Palestinian adults diagnosed with DMT2.
3. To evaluate the relationship between omega-3 index and controlling measurements (blood glucose level, HbA1c, and triglyceride) in selected groups of Palestinian adults diagnosed with DMT2.
4. To examine the correlation between the dietary intake of omega-3 FAs and omega-3 index in selected groups of Palestinian adults diagnosed with DMT2.

### **1.8 Research Questions**

1. What is the level of omega-3 index in the selected groups of Palestinian adults with DMT2?

2. Is there any relationship between omega-3 index and the controlling measurements (blood glucose level, HbA1c, and triglyceride)?
3. What is the average of omega-3 FAs intake among the selected groups of Palestinian adults with DMT2?
4. Is there a correlation between the dietary intake of omega-3 FAs and omega-3 index in the selected groups of Palestinian adults with DMT2?

## CHAPTER 2

### Literature Review

#### 2.1 Relationship between Omega-3 FAs and DMT2

A study conducted by Orang *et al.* (2020) aimed to investigate the effect of omega-3 FAs on inflammatory markers and insulin resistance indices in DMT2 patients in a randomized-double blind clinical trial. Patients with DMT2 were randomly allocated to omega-3 group and placebo group. Omega-3 group used 2 g/ day omega-3 for 12 weeks. Anthropometrics, dietary intake, fasting blood glucose, and HbA1c and serum insulin were assessed before and after the study. 44 participants (aged 49 and 47 for omega-3 group (n = 22) and placebo group (n = 22) group, respectively) finished the study. At the baseline, dietary intake and blood samples analysis did not show any significant differences between groups. Anthropometrics parameters were not statistically different. The results showed  $\beta$  cells function significantly increased in omega-3 group but had no effect on other glycemic and insulin resistance parameters (FBG, HbA1c, HOMA-IR, serum insulin, insulin sensitivity). The study also showed that consuming daily 2 g of omega-3 for 3 months in DMT2 patients significantly increased  $\beta$  cells function, but had no effect on other glycemic and insulin resistance and other inflammatory markers.

Jamilian *et al.* (2017) carried out a meta-analysis based on prospective cohorts to evaluate the effect of omega-3 FAs on the risk of

DMT2. Pooled diabetic risk was calculated using a fixed or random effects model. The dose–response relationship was assessed by meta-regression analysis. Results showed that consumption of single omega-3 FA was associated with an increased risk of DMT2; whereas the relative risk for mixed omega-3 FAs was statistically insignificant. The dose–response curve presented an inverted U-shape of diabetes risk corresponding to the dose of omega-3 consumption. Sub analysis showed that omega-3 was inversely associated with DMT2 risk. The study findings suggested that dosage and composition of omega-3, ethnicity, trial duration, and age could influence the effect of omega-3 on DMT2 progression.

In China, Yao *et al.* (2015) conducted a study to investigate the association between the composition of PUFAs in various tissues and DMT2 among Chinese Han people. A case–control study was employed and included 421 healthy adults and 331 DMT2 patients. Results showed that the ratio of AA/LA, which reflects  $\Delta 6$  desaturase activity, was significantly increased in DMT2 patients. Furthermore, the ratio of EPA/ALA, which reflects  $\Delta 5$  desaturase activity, was markedly decreased in DMT2 patients. Importantly, among four single nucleotide polymorphisms in the FADS1-FADS2 gene cluster, only minor allele (T) of rs174616 was associated with decreased risk of DMT2 in both codominant and dominant models after adjustment for age, gender and BMI. Furthermore, the ratio of AA/LA in both controls and DMT2 was reduced in T carriers while an increased proportion of LA was seen in DMT2 patients compared with control patients. The study concluded that their data

suggest that in northern Han Chinese people, the minor allele (T) of rs174616 in the FADS1-FADS2 gene cluster is associated with a decreased conversion rate of LA to AA, which may contribute to decreased reduced risk of developing DMT2.

A study was performed by Brostow *et al.* (2011) in a Chinese population in Singapore to examine the association between the risk of DMT2 and total omega-3 FAs, omega-6 FAs, marine EPA and DHA, non-marine omega-3 FAs (ALA) and omega-6: omega-3 ratio. The study was performed at the Singapore Chinese Health. The study sample consisted of a 43176 Chinese men and women (free from chronic diseases) within an age group of 45-74 years-old. Whereas the association between the risk of developing DMT2 and FAs intake was examined using cox regression models. Results of the study revealed that DMT2 was inversely associated with the increased intake of total omega-3 FAs. In contrast, the risk of DMT2 was strongly associated with the intake of non-marine omega-3 FAs. In addition, the incidence of DMT2 was not associated with omega-6/omega-3 FAs ratio. However, DMT2 risk was not associated with marine omega-3 FAs (EPA and DHA) (Brostow *et al.*, 2011). Their study concluded that among Chinese Singaporeans, the decreased risk of DMT2 was associated with the ingestion of ALA (nan-marine source of omega-3 FAs) (Brostow *et al.*, 2011).

The association between the risk of DMT2 and long chain omega-3 FAs and consumption of fish and shellfish was examined among middle-aged Chinese population in a prospective population-based cohort study

performed by Villegas *et al.* (2011). The study consisted of a sample of non-diabetic 64,193 women and 51,963 men who were free from cancer and CVD at baseline. Data including the physical activity, anthropometric measurements and dietary intake was collected. The association between risk of DMT2 and long-chain omega-3 FAs and consumption of fish and shellfish was evaluated using Cox regression model. Results indicated that an inversely proportional relationship was found between DMT2 among women and long-chain omega-3 FAs, fish and shellfish consumption (Villegas *et al.*, 2011).

Ramel *et al.* (2008) conducted a study to investigate the effects of seafood consumption on insulin resistance in overweight participants during energy restriction. In an 8-week dietary intervention, 324 participants (20–40 years, BMI 27.5–32.5 kg/m<sup>2</sup>, from Iceland, Spain and Ireland) were randomized to one of four energy-restricted diets of identical macronutrient composition but different long chain omega-3 PUFA content: control ( $n = 80$ ; no seafood; single-blinded); lean fish ( $n = 80$ ; 150 g cod, three times/week); fatty fish ( $n = 84$ ; 150 g salmon, three times/week); (4) fish oil ( $n = 80$ ; daily DHA/EPA capsules, no other seafood; single-blinded). Fasting glucose, insulin, adiponectin, plasma triacylglycerol and FAs in RBCs membrane were measured at baseline and endpoint.

Results indicated that of the participants, 278 (86%) completed the intervention. Fish oil intake was a significant predictor of fasting insulin and insulin resistance after 8 weeks, and this finding remained significant even after including weight loss, triacylglycerol reduction, increased long

chain omega-3 PUFA in membranes or adiponectin changes as covariates in the statistical analysis. Weight loss was also a significant predictor of improvements. Ramel *et al.* (2008) concluded that long chain omega-3 PUFA consumption during energy reduction exerts positive effects on insulin resistance in young overweight individuals, independently from changes in body weight, triacylglycerol, RBC membrane or adiponectin.

Kaushik *et al.* (2009) conducted a cohort study among 195,204 US adults from both genders. The study consisted of 152,700 women and 42,504 men who were free from chronic diseases at baseline from 14-18 years. A validated food-frequency questionnaire was used to assess the intake of long-chain omega-3 FAs and fish at baseline and was updated every 4 years. During these years, 9380 new cases of DMT2 were investigated. And while keeping all other dietary intake and life style factors constant, it was documented that incidence of DMT2 was positively associated with the intake of long-chain omega-3 FAs. The study concluded that there was no evidence that the risk of DMT2 is reduced by the higher intake of fish and long-chain omega-3 FAs. In contrast, the incidence of the disease was moderately increased by the higher intake of these FAs. The study recommended that further investigations should be made to understand the relationship found between DMT2 and long-chain omega-3 FAs, given that these FAs are beneficial when it comes to reduce the risk of cardiovascular diseases (Kaushik *et al.*, 2009).

## 2.2 Relationship between Omega-3 Index and DMT2

In Finland, Takkunen *et al.* (2016) examined the longitudinal associations of serum FA composition with DMT2, insulin secretion and insulin sensitivity over several years. A prospective cohort study derived from the randomized Finnish Diabetes Prevention Study was conducted. Total serum FA composition was measured using GC in 407 overweight, middle-aged people with impaired glucose tolerance at baseline (1993–1998) and annually during the intervention period (1994–2000). The baseline proportions of EPA and DHA were associated with lower incidence of DMT2 during a median follow-up of 11 years. These long-chain omega-3 FAs were associated with higher insulin sensitivity in subsequent years. Whereas, saturated, monounsaturated, transFAs and ALA, LA, were inconsistently associated with DMT2 or related traits. The study concluded that serum long-chain omega-3 FAs predicted lower DMT2 incidence in people at a high risk of diabetes attending to an intervention study; a putative mechanism behind these associations was higher insulin sensitivity.

A study of Albert *et al.* (2014) was made to assess the association between insulin sensitivity and other metabolic outcomes and omega-3 index. The study sample consisted of 47 overweight males at the age of  $46.5 \pm 5.1$  years-old. The assessment was made two times (16 weeks apart). Matsuda method (from oral glucose tolerance test) was used to assess the insulin sensitivity. It was concluded that increased insulin sensitivity and

favorable metabolic profile was associated with higher omega-3 index among overweight men (Albert *et al.*, 2014).

Virtanen *et al.* (2014) investigated the associations between serum omega-3 PUFAs including EPA, docosapentaenoic acid (DPA), DHA, ALA, and risk of incident DMT2 in middle-aged and older Finnish men. A total of 2,212 men from the prospective, population-based Kuopio Ischemic Heart Disease Risk Factor study, aged 42–60 years and free of DMT2 at baseline in 1984–1989, were investigated. Serum PUFA was used as biomarkers for exposure. Dietary intakes were assessed with 4-day food recording. DMT2 was assessed by self-administered questionnaires and fasting and 2-h oral glucose tolerance test blood glucose measurement at reexamination rounds 4, 11, and 20 years after the baseline and by record linkage to hospital discharge registry and reimbursement register on diabetes medication expenses. Results of their study revealed that during the average follow-up of 19.3 years, 422 men developed DMT2.

Men in the highest versus the lowest serum EPA + DPA + DHA quartile had 33% lower multivariate-adjusted risk for DMT2. No statistically significant associations were observed with serum or dietary ALA, dietary fish or EPA + DHA. The study concluded that serum long-chain omega-3 PUFA concentration, an objective biomarker for fish intake, was associated with long-term lower risk of DMT2 (Virtanen *et al.*, 2014).

Djoussé *et al.* (2011) performed a study to evaluate the incidence of DMT2 and omega-3 FAs in plasma. The study sample consisted of 3088 old women and men with an average age of 75 years-old, and it was

performed at the Cardiovascular Health Study from the year 1992 to 2007. In order to measure the plasma omega-3 FAs, GC was used whereas DMT2 was ascertained by testing serum glucose and hypoglycemic agents. Multivariable-adjusted relative risks were estimated by using Cox proportional hazards models (Djousse *et al.*, 2011). Results of the study found out that new cases of DMT2 occurred during the median follow-up of 10.6 years. Several factors were controlled by a multivariable model such as race, sex, body mass index, physical activity, alcohol intake, smoking, clinic site, LA, and LDL cholesterol. It was found that relative risks for DMT2 were 1.0 for reference, 0.96, 1.03, and 0.64 across consecutive quartiles of phospholipid EPA and DHA. Whereas the corresponding relative risks for ALA in phospholipid were 1.0 for reference, 0.93, 0.99 and 0.57. The study concluded that the incidence of DMT2 was not associated with ALA and long-chain omega-3 FAs (by using objective biomarkers). However, lower risk of DMT2 was found in people with the highest concentrations of ALA and long-chain omega-3 FAs (Djousse *et al.*, 2011).

A study by Krachler *et al.* (2008) was conducted in order to investigate the relationship between the development of DMT2 and FAs present in RBCs membrane. The study used a nested case-referent design and included 159 participants who were non-diabetics at baseline and after 5.5 years were diagnosed with DMT2. The study also included 291 control sample (sex and age-matched). The results of the study revealed that increased risk of DMT2 as associated with higher proportions of dihom-

gamma-linolenic, palmitoleic and adrenic acids. Whereas reduced risk of DMT2 was associated with higher proportions of other FAs such as heptadecanoic, pentadecanoic. In addition, DMT2 incidence was inversely associated with clupanodonic and LA (**Krachler *et al.*, 2008**).

## **Chapter 3**

### **Methodology**

#### **3.1 Introduction**

This chapter describes the methods and techniques used in the study, including study design, description of the sample of the study, the formulation of the study tool and validity and reliability measures. In addition, the chapter includes a description of the procedures used in implementing the study and statistical data analysis.

#### **3.2 Study Design**

The current study is a quantitative cross-sectional study

#### **3.3 Study Site and Setting.**

The participants were chosen from Almahfya Clinic in Nablus city among DMT2 patients, since it is a specialized clinic that receives DMT2 patients, in which all the examinations and blood analysis related to the disease are conducted, and where the patient is followed up, disclosed and given all treatment according to WHO recommendations.

#### **3.4 Population and Sample Size**

##### **3.4.1 Population**

The newly reported DMT2 cases visiting the PMoH Primary Health Care diabetic clinics in the West Bank in 2019 reached 5,671 (573 in

Nablus alone). Reaching a total number of 248008 DMT2 cases in the West Bank (Palestinian Ministry of Health, 2019).

### 3.4.2 Sample Size and Sampling Technique

Using the Robert Mason equation below, the sample size of the participants totaled (105) and the convenient sampling method was used to select them.

$$n = \frac{N}{\left[ \left( S^2 \times (N-1) \right) \div pq \right] + 1} \dots\dots\dots(1)$$

**n:** Sample size

**N:** Population size =573

**S:** Standard error 0.05/ 1.96

**P:** Percentage of picking a choice expressed as decimal=0.5

**q=(1-P):0.5**

### 3.4.3 Inclusion Criteria

Participants in the current study are DMT2 patients from Almakhfya clinic in Nablus city from both genders and are more than 30 years old.

### 3.4.4 Exclusion Criteria for Study Group

- Excluding Alzheimer's patient
- Excluding pre-DMT2 patients.

## 3.5 Data Collection Tool

### 3.5.1 Study Questionnaire

A structured questionnaire (Appendix 1) was used to collect the data through interviewing the participants. The questionnaire included the following sections.

### **3.5.1.1 Part One**

#### **3.5.1.1.1 Socio-Demographic Data**

Sex, residency location, marital status, educational level, monthly income, occupational status.

#### **3.5.1.1.2 Information Regarding the Medical History.**

A record of information about a person's health, including information about illnesses (current and past), surgeries, medicines taken and health habits, such as diet and exercise.

#### **3.5.1.1.3 Anthropometric Measurements**

##### **a. Weight.**

An electronic scale was used to measure body weight in kilograms with precision of  $\pm 0.1$  g. Participants were weighed wearing light clothes without shoes, standing in the center of the scale platform, hands resting at sides, looking straight ahead.

##### **b. Height.**

A stadiometer was used to measure participants' height. They were asked to stand straight (head was pointing straight forward) without shoes.

##### **c. BMI**

Results obtained from height and weight measurements were used to calculate BMI as follows:

BMI= weight (Kg) / height (m<sup>2</sup>).....(2).

##### **d. Waist Circumference.**

Waist circumference in cm was taken with the help of putting a measuring tape around a person's waist for both genders.

#### **3.5.1.1.4 Dietary Assessment.**

The FFQ (Appendix 7), modified from Shen *et al.* (2019), was used to assess the omega-3 FAs intake, participants were instructed to describe accurately with details the food portion size during the interview. The participants' responses to FFQ were converted by recoding the answers into numeric values. The recoding was conducted as follows: three points were given for "more than 3 times" answers; two points were given for "1-3 times" answers; one point was given for "0 times". Additionally, for yes or no questions, the answers "yes" were converted into two points and "no" into one point. Data from FFQ was converted manually into average daily intake data using the fact sheet for omega-3 FAs provided from United States Department of Agriculture (USDA, 2020).

#### **3.5.1.2 Part Two**

##### **3.5.1.2.1 Biochemical Tests**

To determine blood glucose level, HbA1c and blood triglyceride levels, blood samples were collected over the period of two months (from 24<sup>th</sup> of September, 2019 till the 5<sup>th</sup> of November, 2019) during the clinic's day hours. In collaboration with the laboratory administration and after participants' approval, blood samples were collected at a medical laboratory with the help of nurses working at Almahfya Clinic in Nablus city. Blood

was drawn from fasting participants. Biochemical tests were done soon after blood collection with the help of nurses at AlMakhfya Clinic.

### **3.5.2 Validity and Reliability**

After a translator translated the data collection tool into Arabic, content validity was used. Finally, the tool was reviewed by experts, the ten copies of the questionnaire were distributed to the doctors from An-Najah National University for their opinion and to ensure the reliability of the questions and the ease of understanding among the participants and to ensure the relevance of the questionnaire to subject under study.

### **3.5.3 Pilot Study.**

A pilot study was conducted on (5%) of the sample size and was included in the sample size. It was conducted to determine the clarity of the questionnaire and to estimate the time necessary for the data collection. The reliability scale (Alpha Cronbach) was computed, with a result of 0.83. This value indicates that the instrument is acceptably valid.

## **3.6 Field work and procedure**

125 blood samples (5.0 ml each) were collected from each participant in EDTA tubes, centrifuged at 4000 rpm at room temperature for 10 minutes to separate cells from the plasma and stored at -60 °C until analysis.

1. Half of the samples were stored at AlMakhfya clinic's laboratory for further biochemical tests (analyzed by nurses and recorded in

participant's medical files) such as HbA1c, blood triglycerides level and blood glucose level.

2. The rest of samples were stored in the laboratory of the Department of Public Health at the An-Najah National University to determine the amount of EPA and DHA in plasma.
3. Omega-3 index was determined using GC system in the Galil society
4. Medical records for each participant was used to obtain all information needed for the research (including medications).

### **3.6.1. Determination of Omega-3 Index**

#### **3.7.1.1. Analysis of Omega-3 FAs**

Omega-3 FAs were determined by the method described by Köhler *et al.* (2010). Blood samples were allowed to melt at room temperature, and three hundred microliters were taken from each blood sample and saponified by mixing with 1ml of KOH in methanol for 15 minutes in a boiling water bath (100 °C). Afterwards, plasma FAs were trans-methylated by adding 1 ml of boron trifluoride (BF<sub>3</sub>) solution in methanol (14%) in a boiling water bath for 10 minutes. FAMES, which resulted from the methylation step, were extracted with 500 microliters of isooctane.

Afterwards, 1.00 microliter was taken from the isooctane layer (upper layer) and injected into the injection port of the gas-liquid chromatography. At this point, FAs composition was analyzed by the GC system at the Galilee Society (the Arab National Society for Health Research and Services).

### **3.6.1.2 Determination of Omega-3 Index.**

The FAMES were determined by comparison of retention time with standards of cis-4,7,10,13,16,19-DHA and cis-5,8,11,14,17-EPA. Omega-3 index was calculated as follows: Omega-3 index= DHA%+ EPA%

### **3.6.1.3 Chemicals and Biochemical Reagents that used to analyze omega 3 index**

NaOH (Batch no. LC24350) and methanol (Batch no. LC 16800) were purchased from LabChem, USA. Boron trifluoride (BF<sub>3</sub>) (Batch no. 109637), isooctane (Batch no. 2087591), cis-4,7,10,13,16,19-Docosahexaenoic acid (Batch no. 6217-54-5) and EPA Method 8260 Standards Kit (Batch no. 48261) were purchased from Sigma-Aldrich, St. Louis, MO, USA.

Agent 1: KOH

Agent 2: BF<sub>3</sub> in MeOH (14%)

Agent 3: isooctane

Agent 4: cis-4,7,10,13,16,19-Docosahexaenoic acid (98%)

Agent 5: cis-5,8,11,14,17-Eicosapentanoic acid analytical standard

### **3.6.1.2 Equipment**

Water bath, centrifuge, GC, glass vials (100 cc) \COD vials, GC vials, EDTA tubes.

### 3.7 Statistical Methods and Data Analysis

After completing data collection, the researcher digitally recorded the data and conducted statistical analysis using the Statistical Package for Social Science (SPSS25).

The following statistical measures were calculated:

1. Frequencies and percentages.
2. Means and standard deviations.
3. Pearson's correlation was used to assess the correlation between omega-3 FAs intake and omega-3 index, omega-3 FAs intake and controlling measurements and between omega-3 index and controlling measurements.

Data was considered significant at  $P < 0.05$ .

**Independent variables:** omega-3 index, omega-3 FAs intake, blood glucose level, HbA1c, triglyceride, age.

**The dependent variable:** comprised DMT2 patients.

**Table 3.1: Conceptual and operational definitions**

Conceptual definition	Operational definition	Reference
Triglyceride: Present in the blood to enable the bidirectional transference of adipose fat and blood glucose from the liver and are a major component of human skin oils.	<ul style="list-style-type: none"> <li>• <math>\leq 150</math>mg/dl. Normal</li> <li>• 150- &lt; 200 mg/dl. Borderline high</li> <li>• 200- &lt; 500 mg/dl. High</li> <li>• <math>\geq 500</math> mg/dl. Very high</li> </ul>	Milleret <i>et al.</i> (2011).
HbA1c Determines the average level of blood sugar over the past 2 to 3 months.	<ul style="list-style-type: none"> <li>• &lt; 6.5. Normal</li> <li>• 6.5 - 7.5. Excellent</li> <li>• 7.5 - 8.5. Good</li> <li>• 8.5 - 9.5. Fair</li> <li>• &gt; 9.5. Poor</li> </ul>	Greci <i>et al.</i> (2003)
Blood Glucose Level	<ul style="list-style-type: none"> <li>• &lt;126. Controllable</li> <li>• <math>\geq 126</math>. Not controllable</li> </ul>	Sopet <i>et al.</i> (2018).

<b>Conceptual definition</b>	<b>Operational definition</b>	<b>Reference</b>
Omega-3 index= %DHA+ %EPA	<ul style="list-style-type: none"> <li>• &lt;4%. Undesirable</li> <li>• 4%-8%. Intermediate</li> <li>• &gt;8%. Desirable</li> </ul>	Harris (2007)
Omega-3 FAs intake Determined by FFQ	The recommended dietary allowance (RDA) for ALA is 1.6 g/day for men and 1.1 gram/ day for women.	Shen <i>et al.</i> (2019).

### **3.8 Ethical Considerations and Accessibility**

The study gained IRB approval from An-Najah National University and the permission from the PMoH to access the clinic (Appendix 3).

. A consent form with data collection tool (Appendix 1) was used to ensure the informed consent of participants in Nablus City after a full verbal explanation about confidentiality and their right to withdraw at any time during the completion of the questionnaire. The approval from PMoH in Ramallah, Nablus and Balata (Appendix 5), and the approval from An-Najah University, Faculty of Graduate Studies (Appendix 4), were gained to conduct the study.

## Chapter 4

### Results

The following part presents descriptive statistics in terms of frequencies and percentages of socio-demographic data analysis, medical history, biochemical tests and anthropometric measurements as well as a clinical omega-3 dietary survey among participants presented by tables.

#### 4.1. Socio –demographic Data

**Table 4.1: Distribution of participants according to their demographic characteristics**

<b>Demographic Characteristics</b>	<b>Category</b>	<b>No</b>	<b>%</b>
Sex	Male	49	46.7
	Female	56	53.3
Marital Status	Married	104	99
	Single	1	1
Educational Level	Illiterate	30	28.6
	Secondary	22	21
	Bachelor	42	40
	Master or more	11	10.4
Occupational Status	Working	49	46.7
	Not working	56	53.3
Age category	<46 years	9	8.6
	46- 60 years	62	59
	>60 years	34	32.4
Mean age $\pm$ SD		(56.81 $\pm$ 8.13)	

Table 4.1 shows characteristics of sample participants presented as frequencies and percentages. Where 56 (53.3%) were females, 104 were married (99%), 42 participants (40%) got Bachelor's degree. Regarding the

occupational status, around 56 (53.3%) are unemployed. 62 participants (59%) were between 46 and 60 years old, the mean age is 56.81 years old  $\pm$  8.13 SD.

## 4.2 Anthropometric Measurements

**Table 4.2: Distribution of participants regarding their anthropometric measurements**

<b>Anthropometric measurements</b>	<b>Category</b>	<b>No</b>	<b>%</b>	<b>Mean <math>\pm</math>SD</b>
Waist Circumference (cm)	Increased	25	23.8	104.42 $\pm$ 13.59
	High	36	34.3	
	Very high	35	33.3	
	Extremely high	9	8.6	
BMI (kg/m <sup>2</sup> )	Normal	5	4.8	32.27 $\pm$ 5.77
	Overweight	31	29.5	
	Obese class1	42	40	
	Obese class2	18	17.1	
	Obese class3	9	8.6	

Table 4.2 presents the anthropometric measurements of the participants. It shows that 40% of participants had a BMI of 42 kg/m<sup>2</sup> (obesity class 1) with a mean of 32.27  $\pm$  5.77 kg/m<sup>2</sup>. On the other hand, 67.6% had high and very high waist circumferences with a mean of 104.42 $\pm$ 13.59cm.

### 4.3 Evaluation of Omega-3 FAs Intake

**Table 4.3: Distribution of percentage of participants according to their omega-3 FAs intake from fish sources**

<b>Omega-3 Dietary Survey from fish</b>	<b>Level</b>	<b>No</b>	<b>%</b>
How many times did you eat fish or shellfish in the past week?	0 times	23	21.9
	1-3 times	73	69.5
	>3 times	9	8.6
Do you take fish oil?	Yes	5	4.8
	No	100	95.2
Weekly intake	Once	2	40
	>2	3	60

Table 4.3 shows omega-3 FAs dietary survey from fish sources conducted among the participants. Out of the total sample, 73 (69.5%) ate fish or shellfish in the past week between 1-3 times. The table also shows that 5 participants (4.8%) took fish oil in the past week. Three participants (60%) took fish oil more than 2 times a week, and two participants took it only once.

**Table 4.4: Distribution of percentage of participants regarding their average omega-3 FAs intake over the last 3 months**

<b>Food type</b>	<b>Level</b>	<b>No</b>	<b>%</b>	<b>Mean <math>\pm</math>SD</b>
Salmon	None	53	50.5	1.29 $\pm$ 2.71
	<3 times	2	1.9	
	$\geq$ 3 times	50	47.6	
Sardine	None	96	91.4	0.76 $\pm$ 2.94
	< 3 times	6	5.7	
	$\geq$ 3 times	3	2.9	
Tuna	None	57	54.3	0.68 $\pm$ 0.93
	<3 times	34	32.4	
	$\geq$ 3 times and more	14	13.3	
Nuts	None	50	47.6	4.33 $\pm$ 4.15
	<3 times	40	38.1	
	$\geq$ 3 times	15	14.3	
<b>Mean intake of omega-3 FAs g/day</b>				<b>1.04<math>\pm</math>0.90</b>

Table 4.4 outlines omega-3 FAs intake, it reveals that the mean intake of omega-3 FAs over the last 3 months was  $1.04 \pm 0.90$  g/ day. It also indicates that 50 (47.6%) participants ate salmon more than 3 times with a mean of  $1.29 \pm 2.71$  g. 9 participants (8.6%) ate sardines regularly at least once per month over the last 3 months with a mean of  $0.76 \pm 2.94$  g. Whereas, 48 (45.7%) ate tuna regularly at least once per month with a mean of  $0.68 \pm 0.93$ g. In addition, 15 (14.3%) participants ate nuts more than 3 times with a mean of  $4.33 \pm 4.15$  g.

#### 4.4 Biochemical Tests

**Table 4.5: Distribution of percentage of participants according to their controlling measurements**

Biochemical test	Category	No	%	Mean $\pm$ SD
HbA1C	Normal < 6.5	12	12.6	8.08 $\pm$ 1.64
	Excellent 6.5 - 7.5	28	29.5	
	Good 7.5 - 8.5	25	26.3	
	Fair 8.5 - 9.5	15	15.8	
	Poor > 9.5	15	15.8	
Blood Glucose level	Controllable <126	8	8.2	173.27 $\pm$ 49.10
	Not controllable ( $\geq$ 126)	90	91.8	
Blood Triglycerides	Normal (<150 mg/dl)	33	34	158.29 $\pm$ 63.60
	Borderline high (150- <200 mg/dl)	57	58.8	
	High (200- <500 mg/dl)	6	6.2	
	Very high ( $\geq$ 500 mg/dl)	1	1	

Table 4.5 presents the results of controlling measurements of the participants. The HbA1C test shows that 29.5% of participants had an excellent level with a mean of  $8.08 \pm 1.64$ . On the other hand, blood glucose level test shows that 90 (91.8%) participants had uncontrollable blood glucose with a mean of  $173.27 \pm 49.10$  mg/dl. In addition, results of blood triglycerides test reveals that 57 (58.8%) participants had a borderline high triglyceride level with a mean of  $158.29 \pm 63.60$  mg/dl.

#### 4.5 Evaluation of FAs and Omega-3 index

**Table 4.6: Mean and SD values of FAs in plasma and omega-3 index of participants**

<b>Variable %</b>	<b>Mean</b>	<b>SD</b>
LA	0.10	0.08
Oleic acid	0.05	0.07
ALA	0.05	0.07
DHA	0.00	0.00
EPA	0.26	2.15
Omega-3 index	0.26	2.15

Table 4.6 outlines the plasma levels of FAs, and the calculated omega-3 index of participants. The data shows that the mean percentage of LA was  $0.10 \% \pm 0.08$ , oleic acid was  $0.05\% \pm 0.07$ , and LA was  $0.05 \% \pm 0.07$ . Whereas, DHA plasma mean percentage was  $0.00 \% \pm 0.00$ , whereas, EPA mean percentage was  $0.26\% \pm 2.15$  and therefore the subsequent omega-3 index was calculated as  $EPA \% + DHA\%$ , and was very low with a mean of  $0.26\% \pm 2.15$ .

## 4.6 Association between Omega-3 Index and Omega-3 FAs Intake

**Table 4.7: Association between omega-3 index and omega-3 FAs intake using Pearson correlation coefficient**

	Omega-3 index		
	N	*r	P- value
<b>Omega-3 FAs intake (g/day)</b>	105	0.047	0.635

Table 4.7 presents the association between omega-3 index and omega-3 FAs intake among the participants. There is a positive ( $P \geq 0.05$ ) association ( $r= 0.047$ ) between omega-3 index and omega-3 FAs intake.

## 4.7 Association between Omega-3 Index and Controlling Measurements

**Table 4.8 Association between omega-3 index and controlling measurements using Pearson correlation coefficient**

Controlling measurement	Omega- 3 index		
	N	*r	P-value
HbA1C	105	-0.021	0.839
Blood glucose	105	-0.14	0.281
Blood triglycerides	105	-0.11	0.286

Table 4.8 shows the association between omega-3 index and HbA1C, blood glucose and blood triglycerides levels among participants. According to the table, there are negative ( $P \geq 0.05$ ) associations between omega-3 index and the controlling measurements (HbA1C, blood glucose and blood triglycerides) among different participants.

## 4.8 Association between Omega-3 FAs Intake and Controlling Measurements

**Table 4.9: Association between omega-3 FAs intake and controlling measurements using Pearson correlation coefficient**

Controlling measurement	Omega-3 FAs intake (g/day)		
	N	*r	P-value
HbA1C	105	-0.18	0.08
Blood glucose	105	-0.13	0.19
Blood triglycerides	105	-0.14	0.15

Table 4.9 presents the association between omega-3 FAs intake and HbA1C, blood glucose, blood triglycerides levels among participants. According to data, there are negative ( $P \geq 0.05$ ) associations between omega-3 FAs intake and HbA1C, blood glucose and blood triglycerides among participants.

## **Chapter 5**

### **Discussion**

#### **5.1 Description of the Study**

This study was conducted to evaluate omega-3 index and intake among Palestinian adults diagnosed with DMT2. It aims also to investigate the relationship between omega-3 index and omega-3 FAs intake and evaluate the relationship between omega-3 index and controlling measurements (blood glucose and triglycerides levels and HbA1C).

Among participants, omega-3 index was extremely low, omega-3 FAs intake was within AMDR values, and there was a linear relationship between omega-3 FAs intake and omega-3 index. On the other hand, biochemical tests have shown that most of the participants had acceptable HbA1c test results, not controllable blood glucose level and borderline high blood triglycerides level. Furthermore, there were inverse relationships between each of the controlling measurements (blood glucose and triglycerides levels and HbA1C) and omega-3 index.

#### **5.2 Evaluation of Anthropometric Measurements**

According to table 4.2, 40% of participants were obese (class 1). In addition, 67.6% had high and very high waist circumferences.

It is well known that obesity complicate the symptoms of DMT2. BMI has a strong relationship to DMT2 and insulin resistance. In obese

individuals, the amount of non-esterified FAs, glycerol, hormones, cytokines, pro-inflammatory markers, and other substances that are involved in the development of insulin resistance, is increased (Al-Goblan *et al.*, 2014). The connection is also seen in the fact that weight-loss can improve control or cure DMT2. In addition to the degree of obesity, where the excess body fat is deposited is important in determining the risk of DMT2. The degree of insulin resistance and the incidence of DMT2 is highest in a person with an “apple” shape. These persons carry the majority of their excess body weight around their abdomen. In contrast, the “pear” shaped person carries most of their weight in the hips and thighs and this is not as likely to be associated with insulin resistance (**Rogers and Still, 2009**).

Furthermore, omega-3 FAs have beneficial effects in lowering triglyceride levels, especially in the post prandial state, including in patients with atherogenic dyslipidemia associated with the metabolic syndrome and diabetes. They are converted into a wide variety of bioactive eicosanoids and act as ligands for several nuclear transcription factors, thereby altering gene expression (**Durrington *et al.*, 2001**).

When comparing tables 4.2 and with table 4.5, it seems that although omega-3 FAs intake (as shown in table 4.4) was sufficiently enough to alleviate increased blood glucose and triglyceride levels, yet participants’ anthropometric measurements, as reflected by their BMI and waist circumference, were highly enough to complicate the consequences of DMT2.

### 5.3 Evaluation of Omega-3 FAs Intake

According to table 4.4, the total omega-3 FAs intake in g/day was estimated as  $1.04 \pm 0.90$ , which indicates that the dietary intake of omega-3 FAs is within the AMDR (0.25-2 g/day) set by WHO and FAO (Joint FAO/WHO, 2008). Indicating that study participants are not likely to suffer from deficiency symptoms associated with EPA and DHA, such as the increased risk of fatal CHD and sudden cardiac death and other complications such as increased blood pressure, impaired cardiac diastolic function, inflammation, elevated triglycerides blood levels (**Mozaffarian and Rimm, 2006**).

The higher omega-3 FAs intake means higher intake of omega-3 rich foods especially those coming from fatty fish, which was consumed in large quantities; e.g. the mean intake of salmon was  $1.29 \pm 2.71$  g/day, where the amount needed to get 500 mg of EPA+DHA/day from salmon is 0.49 g/day, which is higher than required (**Buzby and Hyman, 2012**). In addition, the mean intake of tuna in g/day was  $0.68 \pm 0.93$ , which is also higher than the required amount to get 500 mg of EPA+DHA/day (0.49 g/day). Apart from omega-3 FAs non-marine sources consumed by participants, these two (tuna and salmon) account for more than the required amount. This explains the higher intake of omega-3 FAs.

According to a study by Brostow *et al.* (2011) conducted among Chinese residents of Singapore, marine omega-3 FAs comprised approximately 31% of the population's daily omega-3 and increased total

omega-3 intake was associated with increased seafood intake and overall energy intake. Similar trends were observed in the present study,

#### **5.4 Evaluation of Omega-3 Index**

Data from table 4.6 indicates that omega-3 index value is extremely low, which lies within the high-risk level (Harris, 2007). In general, omega-3 index is higher in countries that consume more omega-3 FAs sources, especially those from fish (Harris and Von Schacky, 2004). e.g., In Japan, whose population has free access to abundant resources of fish and seafood, the average omega-3 index is 9-10% (Harris and Von Schacky, 2004). Although omega-3 FAs intake was relatively high among participants, their omega-3 index lies within the high-risk level set by Harris (2007). The most reasonable explanation for such findings may be attributed to the fact that omega-3 index was calculated from the sum of EPA% and DHA % found in plasma. Whereas, FAs in RBC are more superior since they indicate long-term FAs dietary intake (Katan *et al.*, 1997; Harris, 2009) and due to the fact that the half-life of RBC is 4 to 6 times longer than that of plasma, making FAs in RBC to be less affected by the daily dietary intake of omega-3 FAs (Harris, 2009).

#### **5.5 Relationship between Omega-3 FAs Intake and Index**

It is well known that omega-3 index increases with the increased intake of EPA and DHA (Sala-Vila *et al.*, 2011). A similar trend was observed in the current study, since a positive ( $P \geq 0.05$ ) association was

observed between omega-3 FAs intake and omega-3 index, and as previously mentioned, this could be explained by the fact that omega-3 index calculated from RBC reflects the long-term (3-4 months) consumption of omega-3 FAs, which was insufficient (unreliable) to reflect the long term consumption of omega-3 FAs.

Blocket *al.* (2008) investigated clinical determinants of omega-3 index in 704 outpatients and found that capsules/fish intake together accounted for 47% of the index variability. The Index increased by 13% for each serving level increase in fish intake and EPA+DHA supplementation correlated with a 58% increase regardless of background fish intake.

## **5.6 Relationship between the Omega-3 Index and Controlling Measurements**

### **5.6.1 Relationship between Omega-3 Index and Blood Glucose and HbA1c Levels.**

According to table 4.5, 84.2% of the participants had from fair to excellent HbA1c levels. In this regard, only 15.8% of individuals had poor (>9) test results, which means that most of them had acceptable test results. At the same time, the participants belong to a high-risk group with regard to the omega-3 index (< 4) with nearly zero value. However, according to table 4.5, 91.8 % of participants had not controllable blood glucose levels.

In addition, according to data from table 4.8, an inverse relationship was found between omega-3 index and both blood glucose and HbA1c levels, concluding that higher omega-3 index is associated with decreased

HbA1c level, and therefore increased insulin sensitivity. Our findings are in agreement with Albert *et al.* (2014) regarding HbA1c, who found that higher omega-3 index was associated with increased insulin sensitivity and a more favorable metabolic profile in middle-aged overweight men when they conduct a study to assess whether omega-3 index was associated with insulin sensitivity and other metabolic outcomes in 47 overweight men aged.

A study by Takkunen *et al.* (2016) to examine the longitudinal associations of plasma FAs composition with DMT2, insulin secretion and insulin sensitivity was conducted over several years using a prospective cohort study. Their study concluded that serum long-chain omega-3 FAs were linearly associated with insulin sensitivity and consequently could lower the risk of DMT2 incidence in people at a high risk of diabetes.

### **5.6.2 Relationship between the Omega-3 Index and Blood Triglycerides Level.**

According to biochemical tests (table 4.5), only 34% of participants had normal levels of blood triglycerides. Most of the participants had borderline high level (58.8%), and 7.2% have high or very high levels. In addition, table 4.8 provides a negative relationship between omega-3 index and the blood triglycerides level among participants. Since an inverse association exists, it means that the higher the omega-3 index, the lower is the triglyceride level. Indicating that since omega-3 index approaches zero

for the majority, this was reflected in the borderline high triglyceride blood levels.

Blocket *al.* (2008), investigated the clinical determinants of omega-3 index in 704 outpatients, and found that factors such as fish consumption frequency, triglyceride level, age, high cholesterol history, and smoking explained 59% of omega-3 index variability. Among these, they found that a 100 mg/dl decrease in serum triglycerides was associated with a 15% higher omega-3 index. Therefore, suggesting an inverse association between omega-3 index and blood triglyceride level which is in agreement with the finding of the current study. Furthermore, it is the influence of other factors that might affect omega-3 index rather than triglycerides alone, which may explain the fact that the majority of participants had borderline high triglycerides.

Due to participants' medical condition, high levels of triglycerides are consistent with their disease, which leads to dyslipidemia. Such lipid changes are connected to insulin resistance (Mooradian, 2009). In turn, dyslipidemia can lead to an increased risk of CVDs in DMT2 patients (Mooradian, 2009). Thus, it is important to consume more omega-3 FAs to increase the omega-3 index in DMT2 patients, which may help manage dyslipidemia. The fact that most of the participants are overweight or obese and have high glucose levels in their blood contributes to this theory.

## **5.7 Relationship between Omega-3 FAs Intake and Controlling Measurements**

### **5.7.1 Relationship between Omega-3 FAs Intake and Blood Glucose and HbA1c Levels.**

An inverse relationship was found between omega-3 FAs intake and HHbA1c among participants as shown in table 4.9. It seems that the increased intake of omega-3 FAs had a better glycemic control as shown in table 4.5, since 84.2% of the participants had from fair to excellent HbA1c levels. Never the less, the vast majority had non-controllable blood glucose levels.

According to the Montori *et al.* (2000), omega-3 FAs intake had no adverse effects on glycemic control in people with diabetes. The systematic review by Hartweg *et al.* (2009), reported that omega-3 supplementation was found to lower the plasma level of triglyceride but have no statistical effect on glucose or insulin. However, Brostow *et al.* (2011) highlighted an inverse association between the total intake of omega-3 FAs and the risk of developing DMT2. It is worth noting that in their study, Brostow *et al.* (2011) found that the association between omega-3 FAs from marine sources was null (EPA and DHA); at the same time, there was a strong inverse association between the risk of having diabetes and consumption of non-marine sources of omega 3 FAs (ALA) (Brostow *et al.*, 2011).

A study conducted by Villegas *et al.* (2011) involving over 110000 Chinese citizens also found that there is an inversely proportional (negative)

relationship between DMT2 among women and omega-3 FAs from fish and shellfish consumption. A study by Djousse *et al.* (2011) reached a similar conclusion. According to their results, there is a lower risk of DMT2 in people with the highest concentrations of ALA and long-chain omega-3 FAs.

Overall, the studies conducted by Brostow *et al.* (2011) and Villegas *et al.* (2011) had similar variables and reached a conclusion similar to that of our study. According to their research, there is an inverse relationship between omega-3 intake and the risk of developing DMT2 (Brostow *et al.*, 2011; Villegas *et al.*, 2011).

### **5.7.2 Relationship between the Omega-3 FAs Intake and Blood Triglycerides Level.**

Table 4.9 shows that an inverse association was found between omega-3 FAs intake and blood triglyceride level. Although this relationship means that lower triglycerides should be associated with increased omega-3 FAs intake, yet data from table 4.5 shows inconsistent results. It shows that most participants had borderline high triglyceride blood levels despite their sufficient intake of omega-3 FAs.

Chenet *et al.* (2015) conducted a study to systematically evaluate the effect of omega-3 FAs on glucose control and lipid levels. Among patients with omega-3 supplementation, triglyceride levels were significantly decreased. No marked change in total cholesterol, HbA1c, fasting plasma glucose, postprandial plasma glucose, BMI or body weight was observed.

High ratio of EPA/DHA contributed to a greater decreasing tendency in plasma insulin, HbA1c, triglycerides, and BMI measures, although no statistical significance was identified except for triglycerides.

Skulas-Ray *et al.* (2019) reported that treatment of very high triglycerides with 4 g/day, EPA+DHA agents reduced triglycerides by  $\geq 30\%$  with concurrent increases in low-density lipoprotein cholesterol, and concluded that prescription omega-3 FAs at a dose of 4 g/day ( $>3$  g/day total EPA+DHA) was an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents. These findings support our results, since an inversely proportional relationship was found between omega-3 FAs and triglyceride level.

## **5.8 Strengths of the Study**

Importantly, it is the first study of this kind to be conducted in Palestine. It highlights the level of omega-3 index and the consumption of omega-3 FAs by DMT2 patients, which provides useful data that enables the Palestinian population to make informed dietary choices. As a result, it may help them deal with their medical condition.

## **5.9 Difficulties of the Study**

- The access to the GC system is limited in Palestine, and it is very expensive to use. Thus, it took us a long time to find an association to empower this research.

- According to the association's regulations, the blood test had to be prepared in advance in the An-Najah University Laboratory.

### **5.10 Conclusion**

- It was concluded that the higher the intake of omega-3 FAs, the higher is the omega-3 index as that a linear relationship existed between omega-3 index and omega-3 FAs intake.
- It was also concluded that there was a negative relationship between omega-3 index and DMT2 control measurements, but the relationship was not significant.

### **5.11 Recommendations**

- It is recommended to apply the study including patients with DMT2 from all cities of Palestine.
- In addition, it is recommended to repeat the study findings of omega-3 index by analyzing omega-3 FAs from RBC rather than the plasma.

### **5.12 Implications of the Study**

- Our study has the potential to increase the awareness of the importance of omega-3 FAs consumption in Palestine, especially among the Palestinian patients diagnosed with DMT2.
- There are many international studies that support the claim that omega-3 index and intake affect sensitivity to insulin. Thus, it is necessary to take

in consideration that it may lead to a decrease in the prevalence of DMT2 in Palestine.

- Importantly, such awareness, and as a result, regular consumption of omega-3 FAs has the potential to become a way to manage this medical condition.

### **5.13 Limitations of the Study**

- Due to the lack of reference for the omega-3 index in Palestine, the current study is only a basis for subsequent comprehensive research.
- Analysis of EPA and DHA was based on their content in plasma, it should have been analyzed from RBC phospholipid membrane, since it reflects their long term content and doesn't depend on the feeding status of participants.

## References

- Abu, E. O., & Oluwatowoju, I. (2009). **Omega-3 index determined by gas chromatography with electron impact mass spectrometry.** *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 80(4), 189-194.
- Albert, B. B. Derraik, J.G. Brennan, C.M. Biggs, J.B. Smith, G.C. Garg, M.L. Cameron-Smith, D. Hofman, P.L., & Cutfield, W.S. (2014), **Higher omega-3 index is associated with increased insulin sensitivity and more favourable metabolic profile in middle-aged overweight men.** *Scientific Reports*, 4, 6697.
- Al-Goblan, A. S., Al-Alfi, M. A., & Khan, M. Z. (2014). **Mechanism linking diabetes mellitus and obesity.** *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 7, 587–591.
- Block, R. C. Harris, W. S. Reid, K. J. Sands, S. A. & Spertus, J. A. (2008). **EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls.** *Atherosclerosis*, 197(2), 821-828.
- Bradberry, J. C., & Hilleman, D. E. (2013). **Overview of omega-3 fatty acid therapies.** *Pharmacy and Therapeutics*, 38(11), 681.
- Brostow, D. P., Odegaard, A. O., Koh, W. P., Duval, S., Gross, M. D., Yuan, J. M., & Pereira, M. A. (2011). **Omega-3 fatty acids and incident type 2 diabetes: the Singapore Chinese Health Study.** *The American Journal of Clinical Nutrition*, 94(2), 520-526.

- Budowski, P. (1988).  **$\omega$ 3-fatty acids in health and disease.** *Aspects of Human Nutrition*, 57, p. 214-274.
- Burdge, G. C. Wright, P. Jones, A. E., & Wootton, S. A. (2000). **A method for separation of phosphatidylcholine, triacylglycerol, non-esterified fatty acids and cholesterol esters from plasma by solid-phase extraction.** *British Journal of Nutrition*, 84(5), 781-787.
- Buzby, J. C., & Hyman, J. (2012). **Total and per capita value of food loss in the United States.** *Food Policy*, 37(5), 561-570.
- Chen, C., Yu, X., & Shao, S. (2015). **Effects of omega-3 fatty acid supplementation on glucose control and lipid levels in type 2 diabetes: a meta-analysis.** *PloS One*, 10(10), e0139565.
- Colberg, S. R., Sigal, R. J., Yardley, J. E., Riddell, M. C., Dunstan, D. W., Dempsey, P. C., ... & Tate, D. F. (2016). **Physical activity/exercise and diabetes: a position statement of the American Diabetes Association.** *Diabetes Care*, 39(11), 2065-2079.
- Colosia, A. D. Palencia, R., & Khan, S. (2013). **Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: A systematic literature review.** *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 6, 327.
- Connor, W. E. (2000), **Importance of n- 3 fatty acids in health and disease.** *The American Journal of Clinical Nutrition*, 71(1), 171S-175S.

- Denova-Gutiérrez, E., Ramírez-Silva, I., Rodríguez-Ramírez, S., Jiménez-Aguilar, A., Shamah-Levy, T., & Rivera-Dommarco, J. A. (2016). **Validity of a food frequency questionnaire to assess food intake in Mexican adolescent and adult population.***SaludPública de México*, 58, 617-628.
- Djoussé, L., Biggs, M. L., Lemaitre, R. N., King, I. B., Song, X., Ix, J. H., & Mozaffarian, D. (2011). Plasma omega-3 fatty acids and incident diabetes in older adults. *The American Journal of Clinical Nutrition*, 94(2), 527-533.
- Durrington, P. N., Bhatnagar, D., Mackness, M. I., Morgan, J., Julier, K., Khan, M. A., & France, M. (2001). **An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.** *Heart*, 85(5), 544-548.
- EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). (2012), **Scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA).***EFSA Journal*, 10(7), 2815.
- Ellulu, M. S., Khaza'ai, H., Patimah, I., Rahmat, A., & Abed, Y. (2016). **Effect of long chain omega-3 polyunsaturated fatty acids on inflammation and metabolic markers in hypertensive and/or diabetic obese adults: A randomized controlled trial.** *Food & Nutrition Research*, 60(1), 29268.

- Gebauer, S. K. Psota, T. L. Harris, W. S., & Kris-Etherton, P. M. (2006). **N-3 Fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits.** *The American Journal of Clinical Nutrition*, 83(6), 1526S-1535S.
- Gerster, H. (1998). **Can adults adequately convert a-linolenic acid (18: 3n-3) to eicosapentaenoic acid (20: 5n-3) and docosahexaenoic acid (22: 6n-3)?** *International Journal for Vitamin and Nutrition Research*, 68(3), 159-173.
- Greci, L. S., Kailasam, M., Malkani, S., Katz, D. L., Hulinsky, I., Ahmadi, R., & Nawaz, H. (2003). **Utility of HbA1c levels for diabetes case finding in hospitalized patients with hyperglycemia.** *Diabetes Care*, 26(4), 1064-1068.
- Hague, T. A., & Christoffersen, B. O. (1984). **Effect of dietary fats on arachidonic acid and eicosapentaenoic acid biosynthesis and conversion to C22 fatty acids in isolated liver cells.** *Biochimica et Biophysica Acta*, 796(2), 205-217.
- Hagve, T. A., & Christophersen, B. O. (1986). **Evidence for peroxisomal retro conversion of adrenic acid (22: 4 (n-6)) and docosahexaenoic acids (22: 6 (n-3)) in isolated liver cells.** *Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism*, 875(2), 165-173.
- Harris, W. S. (2007). **Omega-3 fatty acids and cardiovascular disease: A case for omega-3 index as a new risk factor.** *Pharmacological Research*, 55(3), 217-223.

- Harris, W. S. (2009). **The omega-3 index: From biomarker to risk marker to risk factor.** *Current Atherosclerosis Reports*, 11(6), 411.
- Harris, W. S., & Von Schacky, C. (2004). **The omega-3 index: A new risk factor for death from coronary heart disease?** *Preventive Medicine*, 39(1), 212-220.
- Hartweg, J., Farmer, A. J., Holman, R. R., & Neil, A. (2009). **Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes.** *Current opinion in lipidology*, 20(1), 30-38.
- International Diabetic Federation-Diabetes.(2018). **Atlas, 8<sup>th</sup> edition.** Retrieved from November 2, 2018, <http://www.idf.org/diabetesatlas/datavisualisations>.
- Jamilian, M., Samimi, M., Ebrahimi, F. A., Hashemi, T., Taghizadeh, M., Razavi, M., ...&Asemi, Z. (2017). **The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes.** *Journal of Clinical Lipidology*, 11(2), 459-468.
- Joint FAO/WHO Expert Consultation on Fats and Fatty Acids in **Human Nutrition (2008)**. Retrieved from: [https://www.who.int/nutrition/topics/FFA\\_interim\\_recommendations/e/](https://www.who.int/nutrition/topics/FFA_interim_recommendations/e/).
- Katan, M. B. Deslypere, J. P. Van Birgelen, A. P. Penders, M., & Zegwaard, M. (1997). **Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, RBC membranes, and adipose**

- tissue: An 18-month controlled study. *Journal of Lipid Research*, 38(10), 2012-2022.
- Kaushik, M., Mozaffarian, D., Spiegelman, D., Manson, J. E., Willett, W. C., & Hu, F. B. (2009). **Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus.** *The American Journal of Clinical Nutrition*, 90(3), 613-620.
  - Kim, E. S., Im, J. A., Kim, K. C., Park, J. H., Suh, S. H., Kang, E. S., & Lee, H. C. (2007). **Improved insulin sensitivity and adiponectin level after exercise training in obese Korean youth.** *Obesity*, 15(12), 3023-3030.
  - Köhler, A. Bittner, D. Löw, A., & Von Schacky, C. (2010). **Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index.** *British Journal of Nutrition*, 104(5), 729-736.
  - Krachler, B., Norberg, M., Eriksson, J. W., Hallmans, G., Johansson, I., Vessby, B., & Lindahl, B. (2008). **Fatty acid profile of the erythrocyte membrane preceding development of type 2 diabetes mellitus.** *Nutrition, Metabolism and Cardiovascular Diseases*, 18(7), 503-510.
  - Kuriki, K. Tajima, K., & Tokudome, S. (2006). **Accelerated solvent extraction for quantitative measurement of fatty acids in plasma and RBCs.** *Lipids*, 41(6), 605-614.
  - Masood, A., Stark, K. D., & Salem, N. (2005). **A simplified and efficient method for the analysis of fatty acid methyl esters suitable**

- for large clinical studies. *Journal of Lipid Research*, 46(10),2299-2305.**
- Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., ...& Lennie, T. A. (2011). **Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.** *Circulation*, 123(20), 2292-2333.
  - Montori, V. M., Farmer, A., Wollan, P. C., & Dinneen, S. F. (2000). **Fish oil supplementation in type 2 diabetes: a quantitative systematic review.** *Diabetes Care*, 23(9), 1407-1415.
  - Moorodian, D. A. (2009). **Dyslipidemia in Type 2 Diabetes Mellitus.** *Nature Reviews Endocrinology*, 5, 150-159.
  - Mozaffarian, D., & Rimm, E. B. (2006). **Fish intake, contaminants, and human health: Evaluating the risks and the benefits.** *JAMA*, 296(15), 1885-1899.
  - Mulligan, A. A., Luben, R. N., Bhaniani, A., Parry-Smith, D. J., O'Connor, L., Khawaja, A. P., ... & Khaw, K. T. (2014). **A new tool for converting food frequency questionnaire data into nutrient and food group values: FETA research methods and availability.** *BMJ open*, 4(3).
  - Nabavi, S. F., Bilotto, S., Russo, G. L., Orhan, I. E., Habtemariam, S., Daglia, M., Devi, K. P., Loizzo, M. R., Tundis, R., & Nabavi, S. M. (2015). **Omega-3 polyunsaturated fatty acids and cancer: Lessons learned from clinical trials.** *Cancer and Metastasis Reviews*, 34(3), 359-380.

- Orang, Z., Mohsenpour, M. A., & Mozaffari-Khosravi, H. (2020). **Effect of Omega-3 fatty acid supplementation on inflammatory markers and insulin resistance indices in patient with type 2 diabetes and nonalcoholic fatty liver: A randomized double-blind clinical trial.** *Obesity Medicine, 19*, 100278.
- Palestinian ministry of health. (2019). **Health Annual Report.** Retrieved from <http://site.moh.ps/index/Books/BookType/2/Language/a#>
- Ramel, A., Martinez, A., Kiely, M., Morais, G., Bandarra, N. M., & Thorsdottir, I. (2008). **Beneficial effects of long-chain n-3 fatty acids included in an energy-restricted diet on insulin resistance in overweight and obese European young adults.** *Diabetologia, 51*(7), 1261.
- Ratnayake, W. N., & Galli, C. (2009). **Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: A background review paper.** *Annals of Nutrition and Metabolism, 55*(1-3), 8-43.
- Rogers, J. Z., & Still, C. D. (2009). **Obesity and type 2 diabetes.** *Obesity Action Coalition (OAC).*
- Sala-Vila, A., Harris, W.S., Cofán, M., Pérez-Heras, A.M., Pintó, X., Lamuela-Raventós, R.M., Covas, M. I., Estruch, R., & Ros, E. (2011). **Determinants of the omega-3 index in a Mediterranean population at increased risk for CHD.** *British Journal of Nutrition, 106*(3), 425-431.

- Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010). **Global estimates of the prevalence of diabetes for 2010 and 2030.** *Diabetes Research and Clinical Practice*, 87(1), 4-14.
- Shen, W., Weaver, A. M., Salazar, C., Samet, J. M., Diaz-Sanchez, D., & Tong, H. (2019). Validation of a Dietary Questionnaire to Screen Omega-3 Fatty Acids Levels in Healthy Adults. *Nutrients*, 11(7), 1470.
- Simopoulos, A. P. (1991). **Omega-3 fatty acids in health and disease and in growth and development.** *The American Journal of Clinical Nutrition*, 54(3), 438-463.
- Skulas-Ray, A. C., Wilson, P. W., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., ... & Blum, C. B. (2019). **Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association.** *Circulation*, 140(12), e673-e691.
- Sop, J., Gustafson, M., Rorrer, C., Tager, A., & Annie, F. H. (2018). **Undiagnosed diabetes in patients admitted to a clinical decision unit from the emergency department: a retrospective review.** *Cureus*, 10(10).
- Stark, K. D., Van Elswyk, M. E., Higgins, M. R., Weatherford, C. A., & Salem Jr, N. (2016). **Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults.** *Progress in Lipid Research*, 63, 132-152.
- Takkunen, M. J., Schwab, U. S., de Mello, V. D., Eriksson, J. G., Lindström, J., Tuomilehto, J., ... & DPS Study Group. (2016).

- Longitudinal associations of serum fatty acid composition with type 2 diabetes risk and markers of insulin secretion and sensitivity in the Finnish Diabetes Prevention Study.** *European Journal of Nutrition*, 55(3), 967-979.
- **The International Physical Activity Questionnaire.** (2005). Retrieved from [https://sites.google.com/site/theipaq/questionnaire\\_links](https://sites.google.com/site/theipaq/questionnaire_links).
  - Thomas, J., & Garg, M. L. (2016). **Dietary Long Chain Omega-3 Polyunsaturated Fatty Acids and Inflammatory Gene Expression in Type 2 Diabetes.** In *Molecular Nutrition and Diabetes* (pp. 291-299).
  - U.S. Department of Agriculture, **Agricultural Research Service.** (2020). Retrieved from: <https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/#en29>.
  - Villegas, R., Xiang, Y. B., Elasy, T., Li, H. L., Yang, G., Cai, H., & Shu, X. O. (2011). **Fish, shellfish, and long-chain n-3 fatty acid consumption and risk of incident type 2 diabetes in middle-aged Chinese men and women.** *The American Journal of Clinical Nutrition*, 94(2), 543-551.
  - Virtanen, J. K., Mursu, J., Voutilainen, S., Uusitupa, M., & Tuomainen, T. P. (2014). **Serum omega-3 polyunsaturated fatty acids and risk of incident type 2 diabetes in men: the Kuopio Ischemic Heart Disease Risk Factor study.** *Diabetes Care*, 37(1), 189-196.

- Von Schacky, C. (2010). **Omega-3 index and sudden cardiac death.** *Nutrients*, 2(3), 375-388.
- Weylandt, K. H., Serini, S., Chen, Y. Q., Su, H.-M., Lim, K., Cittadini, A., & Calviello, G. (2015). **Omega-3 polyunsaturated fatty acids: The way forward in times of mixed evidence.** *BioMed Research International*, 15(143109): 1-24.
- Yao, M., Li, J., Xie, T., He, T., Fang, L., Shi, Y., ...& Jiang, L. (2015). **Polymorphisms of rs174616 in the FADS1-FADS2 gene cluster is associated with a reduced risk of type 2 diabetes mellitus in northern Han Chinese people.** *Diabetes Research and Clinical Practice*, 109(1), 206-212.

## **Appendices**

### **Appendix 1. English Questionnaire**

Al- Najah National University

Faculty of Graduate Studies

Department of Public Health

#### **Questionnaire to Relationship of Omega-3 status with Diabetes Mellitus**

##### **Type 2 Control Measurements in Nablus City**

Dear Participant,

Peace of Allah, Mercy and blessings on you all

My name is Fatma Bakri, a student perusing my Master's degree of public health in An-Najah National University. Currently I am performing a study that assesses the relationship between omega 3 index and DMT2 control measurements in Nablus city. I would like to kindly request 10 minutes of your time to fill in this questionnaire. Please note that:

Your participation is voluntary and you could refuse or stop anytime with no problem. Your results are confidential and will not be in any way published, the results use will be purely for the researcher to perform and complete the research. (Your name isn't required on the pages of the questionnaire).

Thank you!





**Information regarding Anthropometric Measurements**

Item	Value			
Weight/kg				
Height/m				
Body fat analyzer				
Circumference/cm				
BMI	Underweight = <18.5	Normal weight= 18.5– 24.9	Overweight = 25–29.9	Obesity = BMI of 30 or greater
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**Clinical Omega-3 Dietary Survey**

20. How many times have you eaten fish or shellfish in the past week?

- a) 0 times                      b) 1-3 times                      c) More than 3 times

21. Each time you ate fish or shellfish; how much did you eat?

- a) Less than 50 g or half a fillet or less than 4 pieces/1-2 hand roll of sushi  
b) 100 g or about 1 small fillet or 8 pieces of sushi/3 hand rolls

22. Do you take fish oil:    a) Yes                                      b) No

23. If "Yes", Itake brand:    a)                                      b)                                      c)

24. Type name:                      a)                                      b)                                      c)

25. weekly intake:                      a) once    b) twice    c) more than

26. I take fish oil by:                      a) Grams    b) Caps    c) TBS

**Please, mark the food(s) you eat regularly (i.e., at least once per month) over the last three (3) months and indicate:**

- your average portion for each serve
- on average, how often you eat that type of food



29. During the last 7 days, on how many days did you walk for at least 10 minutes at a time as part of your work? Please do not count any walking you did to travel to or from work:

a) none      b) 1 day      c) between 2-4 days      d) more than 4 days

30. How much time did you usually spend on one of those days walking as part of your work?

a) less than one hour      b) between 1-3 hours      c) more than 3 hours

31. How much time did you usually spend sitting on a weekend day?

a) less than one hour.      b) between 1-3 hours      c) more than 3 hours

## Appendix 2. Arabic Questionnaire

العلاقة بين حالة اوميغا 3 وقياسات التحكم لمريض السكري النوع الثاني في مدينة نابلس

الجنس : ( ذكر \ انثى )      الطول : .....سم      العمر : .....

الوزن : .....      مؤشر كتلة الجسم :  $BMI=Wt.(kg)\Ht.(m)^2$  .....

الخصر : .....

الموقع الجغرافي: .....

الحالها الاجتماعي: متزوج \ اعزب

المرحلة التعليمية: ابتدائي \ ثانوي \ جامعي ..

الدخل :منخفض \ متوسط \ عالي

التاريخ الطبي :

.....

هل تعاني من امراض مزمنة ؟؟ مثل المفاصل \ الضغط العالي ...

.....

هل تعاني من مرض السكر ؟؟؟ نعم \ لا

اذا نعم .. كم من الوقت ؟؟

.....

ما هي الادوية المستعملة لتخفيض نسبة السكر في الدم ؟

.....

ادوية مستعملة بشكل عام مثل ادوية الدهون \ الضغط العالي \ تمييع الدم ...:

.....

مكملات غذائية:

.....

هل تتناول اعشاب معينه بشكل عام؟؟ اذا نعم اذكرها

.....

اتباع حميه غذائيه معينه :

.....

هل يوجد اشخاص مقربين لديهم مرض السكري؟؟

(1) نعم .

(2) لا .

**Biochemical analysis**

**Results**

نتائج تحليل الكيمياء الحيوية

HbA1C

.....

Blood glucose level

.....

Blood triglycerides

.....

Omega 3 index

.....

تناول المصادر الغذائيه للاوميغا 3

كم مرة أكلت السمك في الأسبوع الماضي؟

(1) ولا مره

(2) 1-3 مرات

(3) اكثر من 3 مرات

في كل مرة تأكل فيها السمك ، كم الكمييه ؟

(1) أقل من 50 غرام أو أقل من 4 قطع

(2) 100 غرام أو حوالي 1 شريحة صغيرة

يرجى تحديد الطعام (الأطعمة) التي تتناولها بانتظام (مرة واحدة على الأقل شهرياً) خلال

الأشهر الثلاثة (3) الأخيرة مع الإشارة إلى:

• معدل الكمييه المتناوله من الوجبه

• كم مرة تتناول هذا النوع من الطعام

الاسماك

سلمون ..... غم ..... مره خلال الاسبوع \ الشهر  
 سردين ..... غم ..... مره خلال الاسبوع \ الشهر  
 تونه ..... غم ..... مره خلال الاسبوع \ الشهر

اطعمه اخرى

اللحوم

لحم البقر ..... غم ..... مره في الاسبوع \ الشهر  
 لحم الغنم ..... غم ..... مره في الاسبوع \ الشهر  
 البيض ..... غم ..... مره في الاسبوع \ الشهر

المكسرات

الجوز ..... غم ..... مره في الاسبوع \ الشهر

الكاربوهيدرات

الكميه المتناوله خلال الاسبوع (مثل البطاطا الأرز الباستا ...)

.....

مكملات الاوميغا 3 \ زيت السمك

النوع .....

الجرعه .....

W-3

g/caps/TBS.....

times a day/week.....

النشاط البدني

• هل لديك وظيفة حاليا أو تقوم بأي عمل غير مدفوع الأجر خارج منزلك؟

(1) نعم فعلا

(2) لا

- خلال آخر 7 أيام ، كم عدد الأيام التي قمت فيها بنشاطات جسدية قوية مثل الرفع الثقيل أو الحفر أو البناء الثقيل أو تسلق السلالم كجزء من عملك؟ فكر فقط في الأنشطة البدنية التي قمت بها لمدة 10 دقائق على الأقل في كل مرة

(1) ..... أيام في الأسبوع

(2) ..... لا يوجد نشاط بدني قوي

- خلال آخر 7 أيام ، ما هو عدد الأيام التي سرت فيها لمدة 10 دقائق على الأقل كجزء من عملك؟

(1) ..... أيام في الأسبوع

(2) ..... لم اقم بهذه الفعاليه

- كم من الوقت تقضيه عادة من ايام الاسبوع في المشي كجزء من عملك ؟

(1) ..... ساعة في اليوم

(2) ..... دقائق في اليوم الواحد خلال اخر 7 ايام

- كم من الوقت تقضيه عادة جالس في عطلة نهاية الاسبوع ؟

(1) ..... ساعة في اليوم

(2) ..... دقائق في اليوم الواحد

- هل انت مدخن ؟؟

(1) نعم . كم الفتره .....كم الكميّه ؟؟ .....

(2) لا .

## Appendix 3. An-Najah National University: Institutional Review Board

**(IRB) Ethical**

**Approval**

An-Najah  
National University  
Faculty of medicine  
& Health Sciences  
Department of Graduate  
Studies



جامعة النجاح  
الوطنية  
كلية الطب وعلوم الصحة  
دائرة الدراسات العليا

REF:MAS

Approval Letter

Study Title:

“Relationship of omega 3 index with DM type 2 control measurements in Nablus city”

Submitted by:

Fatma Bakri

Supervisor:

Dr. Mariam Amer Al-Tell

Date Reviewed:

19<sup>th</sup> November 2018

Date Approved:

21<sup>st</sup> November 2018

Your Study titled “Relationship of omega 3 index with DM type 2 control measurements in Nablus city” with archived number (20) November was reviewed by An-Najah National University IRB committee and was approved on 21<sup>st</sup> November 2018

Hasan Fitian, MD

IRB Committee Chairman

An-Najah National University

نابلس - ص.ب 7 أو 707 || هاتف (970) (09) 2342902/4/7/8/14 || فاكس (970) (09) 2342910

Nablus - P.O Box :7 or 707 | Tel (970) (09) 2342902/4/7/8/14 | Faximile (970) (09) 2342910 | E-mail : hgs@najah.edu



## Appendix 5. Palestinian Ministry of Health's Letter of Approval

State of Palestine  
Ministry of Health - Nablus  
General Directorate of Education in  
Health



دولة فلسطين  
وزارة الصحة- نابلس  
الإدارة العامة للتعليم الصحي

Ref: .....  
Date:.....

الرقم: ٢٠١٩ / ٩٧٤ / ٤٤٤  
التاريخ: ٢٠١٩ / ١١ / ١٤

الأخ مدير عام الادارة العامة للرعاية الصحية الأولية المحترم،،،  
تحية واحترام،،،

### الموضوع: تسهيل مهمة - جامعة النجاح

يرجى تسهيل مهمة الطالبة: فاطمة هشام احمد بكري- تخصص ماجستير صحة عامة/ جامعة النجاح، في عمل بحث بعنوان "العلاقة بين مؤشر اوميغا 3 وقياسات التحكم لمريض السكري النوع الثاني في مدينة نابلس"، من خلال السماح للطالبة بجمع معلومات تتعلق بالبحث من خلال تعبئة استبانة الدراسة من مرضى السكري، وسحب عينة دم لقياس مؤشر اوميغا 3 (بعد اخذ موافقتهم) ومراجعة ملفات المرضى، وذلك في:

- عيادة السكري (المخفية) في مديرية صحة نابلس

علما ان البحث تحت اشراف د. مريم الطل، والفنيين الذين سيقومون بسحب العينات هم:

- فني المختبر: علي عادل رضوان (مرفق مزاوله المهنة)

- الممرض: نادر محمد احمد عمرو (مرفق مزاوله المهنة)

كما انه سيتم الالتزام بمعايير البحث العلمي والحفاظ على سرية المعلومات.

مع الاحترام،،،



نسخة: عميد كلية الدراسات العليا المحترم/ جامعة النجاح

## Appendix 6. The Distribution of Omega-3 Intake Regarding the Food Type Participants

### Eat Regularly over the Last Three (3) Months

Serial Number	Salmon	Sardine	Tuna	Beef	Lamb	Eggs	Nuts	Average
1	0.00	1.26	0.20	0.04	0.04	0.00	8.26	1.40
2	0.00	0.00	0.20	0.04	0.00	0.12	8.26	1.23
3	1.94	0.00	0.20	0.04	0.04	0.12	0.00	0.33
4	0.00	0.00	0.20	0.00	0.00	0.12	0.00	0.05
5	0.00	0.00	0.20	0.04	0.00	0.12	0.00	0.05
6	0.00	0.00	0.20	0.04	0.00	0.18	8.26	1.24
7	0.00	0.00	0.20	0.00	0.42	0.18	8.26	1.29
8	0.00	1.26	0.20	0.00	0.00	0.12	8.26	1.41
9	1.94	0.00	0.00	0.00	0.00	0.18	8.26	1.48
10	1.94	0.00	0.20	0.04	0.00	0.18	8.26	1.52
11	0.00	0.00	2.01	0.00	0.00	0.18	8.26	1.49
12	1.94	0.00	0.00	0.00	0.00	0.12	8.26	1.47
13	0.00	12.60	0.20	0.04	0.00	0.18	0.00	1.86
14	0.00	0.00	0.00	0.00	0.00	0.18	8.26	1.21
15	19.38	0.00	0.20	0.42	0.00	0.00	8.26	4.04
16	0.00	1.26	0.20	0.00	0.00	0.12	8.26	1.41
17	0.00	0.00	0.00	0.00	0.00	0.12	8.26	1.20
18	19.38	0.00	0.00	0.00	0.00	0.12	0.00	2.79
19	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.03
20	1.94	0.00	0.00	0.00	0.00	0.12	8.26	1.47
21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
23	0.00	0.00	0.20	0.00	0.00	0.18	0.00	0.05
24	1.94	12.60	0.20	0.42	0.00	0.18	8.26	3.37
25	1.94	0.00	0.00	0.00	0.00	0.18	0.00	0.30
26	0.00	0.00	2.01	0.42	0.00	0.12	8.26	1.55
27	0.00	0.00	0.00	0.00	0.00	0.18	8.26	1.21
28	0.00	0.00	2.01	0.42	0.00	0.18	8.26	1.55
29	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.03
30	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.03
31	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.03
32	0.00	0.00	2.01	0.42	0.00	0.18	0.00	0.37
33	0.00	0.00	0.00	0.00	0.00	0.12	0.00	0.02
34	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.03
35	0.00	0.00	0.00	0.00	0.00	0.18	8.26	1.21
36	1.94	12.60	2.01	0.42	0.42	0.18	8.26	3.69

Serial Number	Salmon	Sardine	Tuna	Beef	Lamb	Eggs	Nuts	Average
37	1.94	0.00	2.01	0.00	0.00	0.18	0.00	0.59
38	1.94	0.00	2.01	0.42	0.42	0.18	8.26	1.89
39	1.94	0.00	0.00	0.04	0.42	0.18	0.00	0.37
40	1.94	12.60	2.01	0.04	0.42	0.18	0.00	2.46
41	0.00	12.60	0.00	0.04	0.00	0.00	0.00	1.81
42	1.94	0.00	0.00	0.00	0.00	0.18	0.00	0.30
43	1.94	0.00	0.00	0.04	0.00	0.18	0.00	0.31
44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
45	1.94	0.00	0.00	0.00	0.00	0.18	0.00	0.30
46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
47	1.94	0.00	0.00	0.04	0.04	0.18	8.26	1.49
48	1.94	12.60	2.01	0.04	0.04	0.18	8.26	3.58
49	1.94	0.00	0.00	0.00	0.04	0.18	8.26	1.49
50	1.94	0.00	2.01	0.00	0.04	0.00	0.00	0.57
51	0.00	0.00	0.00	0.00	0.00	0.12	0.00	0.02
52	1.94	0.00	2.01	0.42	0.42	0.18	8.26	1.89
53	1.94	0.00	0.00	0.00	0.42	0.18	8.26	1.54
54	1.94	0.00	2.01	0.42	0.00	0.18	0.00	0.65
55	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
56	0.00	0.00	0.00	0.42	0.04	0.18	8.26	1.27
57	0.00	0.00	0.00	0.00	0.04	0.18	8.26	1.21
58	1.94	0.00	2.01	0.42	0.04	0.18	8.26	1.84
59	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
65	1.94	0.00	2.01	0.42	0.04	0.18	8.26	1.84
66	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
68	1.94	0.00	2.01	0.42	0.04	0.18	8.26	1.84
69	1.94	0.00	2.01	0.00	0.00	0.18	8.26	1.77
70	1.94	0.00	2.01	0.00	0.00	0.18	8.26	1.77
71	1.94	0.00	2.01	0.00	0.00	0.18	8.26	1.77
72	0.00	0.00	0.00	0.00	0.00	0.12	8.26	1.20
73	0.00	0.00	0.00	0.00	0.00	0.18	8.26	1.21
74	0.00	0.00	0.00	0.00	0.00	0.18	8.26	1.21
75	0.00	0.00	0.00	0.00	0.00	0.18	8.26	1.21
76	0.00	0.00	0.00	0.00	0.00	0.18	8.26	1.21
77	1.94	0.00	2.01	0.00	0.00	0.12	8.26	1.76
78	1.94	0.00	2.01	0.00	0.00	0.18	8.26	1.77

Serial Number	Salmon	Sardine	Tuna	Beef	Lamb	Eggs	Nuts	Average
79	1.94	0.00	2.01	0.00	0.00	0.18	8.26	1.77
80	1.94	0.00	2.01	0.00	0.00	0.18	8.26	1.77
81	1.94	0.00	2.01	0.00	0.00	0.18	8.26	1.77
82	0.00	0.00	0.00	0.00	0.00	0.00	8.26	1.18
83	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
85	1.94	0.00	2.01	0.42	0.42	0.18	8.26	1.89
86	1.94	0.00	2.01	0.00	0.00	0.18	8.26	1.77
87	1.94	0.00	2.01	0.00	0.00	0.18	8.26	1.77
88	1.94	0.00	2.01	0.00	0.00	0.18	8.26	1.77
89	0.00	0.00	0.00	0.00	0.00	0.12	8.26	1.20
90	1.94	0.00	0.00	0.00	0.00	0.18	8.26	1.48
91	1.94	0.00	0.00	0.00	0.00	0.18	8.26	1.48
92	1.94	0.00	0.00	0.00	0.00	0.18	8.26	1.48
93	1.94	0.00	0.00	0.00	0.00	0.18	8.26	1.48
94	1.94	0.00	2.01	0.00	0.00	0.18	8.26	1.77
95	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.03
96	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.03
97	1.94	0.00	2.01	0.00	0.00	0.18	0.00	0.59
98	1.94	0.00	0.00	0.00	0.00	0.18	0.00	0.30
99	1.94	0.00	2.01	0.00	0.00	0.18	0.00	0.59
100	1.94	0.00	0.00	0.00	0.00	0.00	0.00	0.28
101	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.03
102	1.94	0.00	2.01	0.00	0.00	0.18	0.00	0.59
103	1.94	0.00	2.01	0.00	0.00	0.12	0.00	0.58
104	1.94	0.00	2.01	0.00	0.00	0.12	0.00	0.58
105	1.94	0.00	2.01	0.00	0.00	0.18	0.00	0.59
<b>Average of Omega-3 Intake</b>	<b>1.04</b>							

It is clear from the table above that the highest average of omega3 intake was 4.04, and the lowest was 0.00. This means that the participants did not eat any of these foods for the last three months. The average omega-3 intake for 46 (43%) participants is less than 1, while 53 (50%) have between 1 and less than 2, and only 5 (6%) have between 2 and 4.04.

## Appendix 7.

## قائمة المتناول من الطعام

كيفية تسجيل الكمية المتناولة من الاطعمة

كيفية تقدير حجم الوجبة المقدمة:

	<p><b>اللحوم</b> 3 اونصات من اللحم = حجم علبة الشدة</p>
	<p><b>الفواكه</b> حجم طابطة التنس. = تقاحة متوسطة</p>
	<p><b>الحبوب</b> كوب الارز = حجم قبضة اليد</p>
	<p><b>الاجبان</b> اونصة من الجبن = حجم 4 قطع نرد</p>

جامعة النجاح الوطنية  
كلية الدراسات العليا

العلاقة بين حالة أوميغا 3 وقياسات التحكم لمريض السكري النوع

الثاني في مدينة نابلس

اعداد

فاطمة هشام بكري

إشراف

د. مريم الطل

د. نهال ناطور

قدمت هذه الأطروحة استكمالاً لمتطلبات الحصول على درجة الماجستير في برنامج الصحة العامة، بكلية الدراسات العليا، في جامعة النجاح الوطنية، نابلس- فلسطين

2020

ب

العلاقة بين حالة اوميجا 3 وقياسات التحكم لمريض السكري النوع الثاني في مدينة نابلس

إعداد

فاطمة هشام بكري

إشراف

د. مريم الطل

د. نهال ناطور

## الملخص

تشير دراسات مختلفة إلى أن الكمية الغذائية المستهلكة من أحماض أوميغا3 الدهنية تساعد على إمكانية منع حدوث امراض خطيرة، بما في ذلك مرض السكري من النوع الثاني. بالرغم أن مرض السكري من النوع الثاني هو أحد الأمراض المزمنة الرئيسية في فلسطين، فإن مؤشر أوميغا3 لم يتم تقييمه بينالبالغين الفلسطينيين الأصحاء أو الذين تم تشخيصهم بمرض السكري من النوع الثاني على مستوى السكان.

### هدف الدراسة:

هدفت الدراسة الى تقييم حالة أوميجا3 في مجموعة مختارة من البالغين الفلسطينيين الذين تم تشخيصهم بمرض السكري من النوع الثاني.

### منهجية الدراسة:

أجريت دراسة مقطعية شملت عينة من 105 مريض سكري فلسطيني من النوع الثاني في مدينة نابلس. تم تقييم الاستهلاك الإجمالي لأحماض أوميجا 3 الدهنية خلال الأشهر الثلاثة الماضية باستخدام استبيان تواتر الغذاء. تم تحليل قياسات التحكم بما في ذلك الهيموغلوبين السكري ومستوى السكر في الدم ومستوى الدهون الثلاثية في الدم بعد الحصول على عينات الدم من كل مريض. بينما تم تحليل الاحماض الدهنية باستخدام كروماتوجرافيا الغاز.

## النتائج

كان مؤشر أوميغا 3 منخفضا للغاية بمتوسط  $2.15 \pm 0.26$ ، وكان متوسط استهلاك أحماض أوميغا 3 الدهنية  $0.90 \pm 1.04$  غ/يوم وهو ما كان ضمن قيم نطاق توزيع المغذيات الكبيرة المقبول. بالإضافة إلى ذلك، كانت هناك علاقة إيجابية ( $r = 0.047$ ) ولكن ليست ذات دلالة احصائية ( $P \leq 0.05$ ) بين الكمية المستهلكة من أحماض أوميغا 3 الدهنية ومؤشر أوميغا 3. ومن ناحية أخرى، كانت هناك علاقات سلبية ولكن ليست ذات دلالة إحصائية ( $P \leq 0.05$ ) بين مؤشر أوميغا 3 وهيموغلوبين السكري ( $r = -0.021$ )، ومؤشر أوميغا 3 ومستوى سكر الدم ( $r = -0.14$ ) وبين مؤشر أوميغا 3 ومستوى الدهون الثلاثية في الدم ( $r = -0.11$ ).

## الخلاصة

استنتجت الدراسة على وجود علاقة خطية بين مؤشر أوميغا 3 والمتناول من أحماض أوميغا 3 الدهنية. أي أنه كلما زاد المتناول، كلما زاد مؤشر أوميغا 3. واستنتجت الدراسة أيضا الى ان الاستهلاك الكافي من أحماض أوميغا 3 الدهنية له تأثير خافض على مستوى السكر في الدم، ونسبة هيموغلوبين السكري ومستوى الدهون الثلاثية في الدم.

## التوصيات

نوصي أصحاب المصلحة بتقييم مؤشر أوميغا 3 بين مرضى السكري من النوع الثاني في كريات الدم الحمراء بدلا من البلازما وتطبيق الدراسة على مرضى السكري من النوع الثاني في كل مدن فلسطين.

## الكلمات الأساسية

كمية أحماض أوميغا 3 المستهلكة، مؤشر أوميغا 3، مرض السكري من النوع الثاني، كروماتوجرافيا الغاز، قياسات التحكم.